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The Role of EZH2 in Breast Cancer Progression and Metastasis 
 
 
Breast cancer is the second leading cause of cancer-related deaths for women in 
the United States, with the majority due to the development of distant metastasis. 
Understanding how breast cancer cells disseminate and metastasize is essential to 
develop more efficacious treatments and to improve survival. Enhancer of Zeste 
Homolog 2 (EZH2) is a Polycomb group protein which functions mainly as a 
transcriptional repressor through histone trimethylation. Our laboratory has found that 
EZH2 overexpression in clinical samples of invasive breast carcinomas is associated 
with worse survival. Here, we have focused our work on elucidating the functions and 
mechanisms by which EZH2 promotes aggressive breast carcinomas with metastatic 
potential. We have found that EZH2 regulates two important processes for metastasis: 
the epithelial-to-mesenchymal transition and migration, and the numbers of breast 
cancer stem cells.  
We discovered that downregulation of EZH2 in aggressive and metastasizing 
breast cancer cells promotes a mesenchymal-to-epithelial transition and reduces 
motility and invasion. In vivo, EZH2 knockdown in breast cancer cells decreased 
spontaneous metastasis to the lungs. We uncovered an unexpected role of EZH2 in 
inducing the p38 signaling pathway, a known regulator of breast cancer invasion and 
metastasis. EZH2 was demonstrated to bind phosphorylated-p38 (p-p38) in association 
 
xi 
with other core members of the Polycomb Repressive Complex 2 (PRC2). Moreover, 
the effect of p-p38 was confirmed in vivo and correlated with decreased spontaneous 
metastasis. Through analysis of invasive human breast cancers, we found that EZH2 
expression was upregulated in all cases, and that EZH2 and p-p38 were co-expressed 
in 63% of cases, consistent with the functional results.  
In our studies on the role of EZH2 in breast cancer stem cell biology, we found 
that EZH2 expression levels regulate stem cell numbers in nontumorigenic and 
malignant breast cells. Mechanistically, we revealed a novel role of EZH2 in activating 
Notch1 signaling through binding of the Notch1 promoter. Binding was independent of 
its catalytic methyltransferase activity and PRC2, and correlated instead with 
transcriptional activation. Notch1 inhibition was sufficient in preventing the EZH2-
induced expansion of the stem cell population. In a transgenic mouse model with 
targeted EZH2 overexpression, we found that EZH2 promoted earlier breast cancer 
initiation and correlated with Notch1 expression. Additionally, EZH2, Notch1 and stem 
cell markers were found to correlate in human breast cancer. Taken together, these 
findings reveal important and novel functional links between EZH2, stem cells and 
breast cancer migration and invasion, and their underlying mechanisms involving EZH2-
mediated regulation of p38 and Notch1 signaling pathways. Our work establishes EZH2 
as a regulator of breast cancer progression and metastasis, and identifies potential 







1-1. The Human Mammary Gland and Breast Cancer Development 
Mammals are distinguished from all other animal groups by the presence of a 
unique organ, the mammary gland, which functions in secreting milk to nourish young. 
The development of the mammary gland is divided into three stages: embryonic, 
pubertal and reproductive [1]. Proper maintenance and control of these temporal stages 
are essential for correct development and tissue homeostasis. Unfortunately, when 
aberrations in these developmental processes transpire during the postnatal life of a 
female, uncontrolled cell growth and subsequent breast cancer may result.  
For women in the United States, breast cancer is the most common malignancy 
and is also the second most common cause of cancer-related deaths behind lung 
cancer [2]. It is currently estimated that a women living in the United States has a 1 in 8 
lifetime risk of being diagnosed with breast cancer. Better screening and treatment 
strategies have resulted in improved survival and quality of life in breast cancer patients 
as demonstrated in a yearly 2.2% decrease in breast cancer death rates since 1990 [2]. 
However, although death rates are decreasing, approximately 40,000 women were 
expected to die from breast cancer in 2011 alone [2]. Even though breast cancer 
incidence rates have remained relatively stable since 2003, approximately 288,000 new 
cases of in situ and invasive breast cancer were expected to be diagnosed among 
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women in 2011 [2]. Research, ranging from basic to clinical, into the mechanisms 
behind breast cancer development and progression are responsible for the improving 
trend in breast cancer statistics, but more research is needed to see further reductions 
in incidence and death rates.  
It is important to note that breast cancer cannot be considered a single disease. 
It is rather a heterogeneous mix of breast malignancies that exhibit various genetic, 
epigenetic and genomic alterations, which can have diverse histological presentations 
and outcomes in patients. This diversity has led to the subdivision of breast cancer into 
four main molecular classes based on gene expression profiling: luminal A, luminal B, 
basal-like or triple-negative and HER2/ERBB2-overexpressing [3, 4]. Our current theory 
on breast cancer is that it develops along a continuum within the epithelium of breast 
[5]. Breast ducts and acini exhibit a bilayer of two cell types present in roughly equal 
numbers: an outer layer of elongated, myoepithelial cells surrounding an inner lining of 
polarized, luminal epithelial cells [1, 6-8]. The bilayered ducts form a branching structure 
throughout the breast that end in clusters of small secretory acini that compose the 
terminal-ductal-lobular-units (TDLUs), or lobules. By birth, a female has a rudimentary 
ductal tree that grows isometrically to the rest of the body up until puberty. During 
puberty and pregnancy, the epithelium undergoes great proliferation and expansion, but 
the mammary glands do not reach full maturity until pregnancy. During pregnancy, the 
luminal cells within the TDLUs become alveolar cells that produce milk proteins. 
Functionally, the myoepithelial cells contract upon hormone stimulation during lactation 
allowing for release of milk from the luminal cells into the lumen, which travels through 
the ducts to the nipple. Following pregnancy, the TDLUs involute decreasing in number, 
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but the cycle of proliferation and expansion can be repeated with subsequent 
pregnancies until a woman is no longer able to conceive. At all stages, the ducts and 
lobules are enclosed by a continuous, laminin-rich basement membrane (BM), which 
separates the epithelium from the collagenous stroma. The tree-like structure of the 
epithelium is supported by the stroma, which is also referred to as the mammary fat 
pad, extending its branches throughout this tissue. The stroma is composed of 
adipocytes, blood vessels, nerves, fibroblasts and immune cells, all of which help in the 
development and maintenance of the mammary gland. 
The linear continuum of breast cancer development postulates that epithelial 
cells within the TDLUs progress through stages of alterations that may eventually 
advance into invasive breast carcinoma and metastasis (Figure 1-1, A) [5, 9]. Breast 
cancer may initiate with epithelial hyperplasia in the TDLUs. A small proportion of these 
hyperplastic cells may develop atypia and progress into atypical hyperplasia (AH), either 
ductal or lobular, if the hyperplastic cells begin to layer and take on an abnormal 
appearance. AH is considered a non-obligate precursor to cancer as only about 20% of 
patients with AH will go on to develop to cancer within 15 years of diagnosis [10]. AH 
may progress into ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), 
which are defined as noninvasive malignant lesions. Of the estimated 58,000 in situ 
cases diagnosed yearly, the majority, approximately 83%, are classified as DCIS, while 
LCIS accounts for about 11% of in situ cancer cases [2]. As DCIS and LCIS lesions are 
in most cases excised, there are limited available data on the percentage of in situ 
carcinomas that would be expected to progress to invasive breast cancer. However, 
data indicate that the 10-year mortality rate for patients with DCIS is less than 2% after 
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excision or mastectomy [11-13]. A diagnosis of invasive breast cancer is confirmed 
when the malignant epithelial cells escape the confines of the duct or lobule by breaking 
through the surrounding BM into the stroma. Once invasive breast cancer develops, the 
risk for developing metastasis significantly increases. The five-year survival rate for 
women with regional breast cancer metastasis, meaning it has mainly spread to the 
axillary lymph nodes, is 84%, but unfortunately, the same rate for women with 
metastasis to distant organs is a mere 23% [2]. Even with progress in research, 
however, metastatic breast cancer is considered essentially incurable and most deaths 
from breast cancer occur as a result of metastasis. More research aiming to understand 
the mechanisms involved in the progression of breast cancer from in situ to invasive 
and metastatic stages is needed for the development of better treatment strategies and 
survival.   
The linear model of tumor progression holds to the traditional view that a single 
cell of origin gains genetic variability and a clonal expansion of more aggressive cells 
evolves with time [5, 9]. This generally implies that most primary cells have low 
metastatic potential and that metastasis-driving mutations are acquired during later 
stages of tumorigenesis. With this model, metastatic dissemination is expected to occur 
as a late process and to correlate with primary tumor size, and this does hold true in 
most cases [14]. Further support for this model is seen in studies showing that primary 
tumors and their matched metastases have similar molecular signatures [15-17]. In 
addition, mutations associated with driving metastasis are more likely to be seen in 
metastatic cells versus cells from the primary tumor site [18, 19].  
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 It is important to recognize that the linear progression for breast cancer 
development described above is only a model and deviations do occur. For instance, 
observations have suggested that breast cancer cells may acquire the ability to 
disseminate early during tumor progression, perhaps even during a premalignant stage 
[20]. This parallel model for metastasis implies that metastatic breast cancer cells may 
evolve independently from the primary tumor [20, 21]. Indeed, clinical analysis of a large 
cohort of breast cancer patients indicated that metastasis may be initiated before 
diagnosis of the primary tumor and that survival following metastasis was almost 
unrelated to primary tumor size [22]. Husemann and colleagues demonstrated that 
malignant cells were detected in the circulation and in the bone marrow of patients with 
DCIS [23]. In further support, research has shown that disseminated cancer cells from 
breast cancer patients display fewer genetic alterations when compared to cells isolated 
from the primary tumor [21, 23-25]. In reference to this model, attention should be paid 
to delineating the genetic alterations in disseminated cancer cells, as presence of these 
cells in the bone marrow of breast cancer patients has been shown to be an 
independent indicator of recurrence [26]. It is possible to characterize breast cancer 
cells circulating in the peripheral blood or disseminated to the bone marrow, and these 
characterizations may provide important information on predicting response to therapies 
in metastatic breast cancer [27]. In addition, genetic studies on disseminated tumor cells 
may allow for earlier detection of metastasis. Taken together, there is no defined set of 
standards on how, when or where breast cancer progresses to a metastatic state. The 
linear and parallel models should remain as no more than broad guidelines being 
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applied on an individual basis as metastatic capability may arise early or late during 
breast cancer progression.  
 
1-2. The Breast Cancer Metastatic Cascade 
 The metastatic cascade collectively describes the complex multistep process that 
allows tumor cells to leave the primary site and establish a distant colony (Figure 1-1, 
B). The major stages breast cancer cells undergo in this succession of biological events 
are characterized as (1) local invasion through the basement membrane into 
surrounding stromal tissues, (2) intravasation into blood vessels, (3) survival during 
dissemination through vasculature, (4) arrest and extravasation at distant sites, (5) 
survival in new microenvironment and (6) re-initiation of proliferative capabilities at the 
metastatic site [18, 20]. These basic steps will be described in more detail in the 
following sections.  
 
Invasion, Migration and the Role of the Epithelial-to-Mesenchymal Transition 
As previously mentioned, progression from carcinoma in situ to invasive breast 
carcinoma occurs when tumor cells gain access to the stroma by breaking through the 
well-confined barrier of the surrounding BM. One of the first alterations required of 
tumor cells to invade is the loss of cell-to-cell adhesion and adhesion to the BM. Studies 
have shown that tumor cells may utilize the process of an epithelial-to-mesenchymal 
transition (EMT), where epithelial cells undergo transdifferentiation to mesenchymal 
cells to move and invade [28-32]. Expanding on the previous definition, breast epithelial 
cells are tightly bound together through cell-to-cell adhesion complexes forming a sheet 
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of columnar cells that display an apico-basal cell polarity. In contrast, mesenchymal 
cells throughout the body lack intercellular junctions, act individually and possess motile 
abilities. Thus, a switch of tumorigenic epithelial cells to a mesenchymal phenotype 
might enable migration and invasion. 
EMT events were first described in nontumorigenic cells [29, 30]. Type 1 EMT 
occurs during embryogenesis and is first observed at gastrulation with the formation of 
the primitive streak. Type 2 EMT takes place during instances of inflammation, such as 
at times of wound healing and tissue regeneration. Focus on metastasis research has 
led to the development of Type 3 EMT, or oncogenic EMT, where carcinoma cells may 
gain characteristics of mesenchymal cells allowing for detachment from the primary 
tumor, invasion and intravasation. Recent studies in mouse models and in human 
tumors provide evidence for oncogenic EMT [33-35]. In a study where almost 500 
invasive breast carcinomas were analyzed for different markers, protein expression 
patterns associated with a mesenchymal phenotype were found to associate in basal-
like tumors, the most aggressive breast cancer molecular subtype, signifying a 
relationship between mesenchymal differentiation and metastatic capabilities [36]. In 
most cases of oncogenic EMT, the transition is considered only partial, as tumor cells 
may not fully lose epithelial characteristics [30]. Also, as metastases usually appear 
histologically similar to their primary tumor counterparts, it has been suggested that 
tumor cells at a metastatic site may undergo a mesenchymal-to-epithelial transition 
(MET) emphasizing the plasticity of these transitions [37].  
E-cadherin, considered a marker protein of epithelial cells, is well documented in 
mediating cell-to-cell junctions and its downregulation has been associated with 
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metastasis and poor prognosis in breast cancer [28, 38-40]. Several mesenchymal-
related transcription factors, such as Snail1, Snail2, Twist1, ZEB1 and ZEB2, have been 
shown to regulate EMT, with some even directly repressing levels of E-cadherin, and 
their upregulation is also associated with poor prognosis [18, 28-30]. Moreover, several 
signaling pathways, including TGF-β, EGF, Wnt, Notch, and Hedgehog, have all been 
found to induce EMT in breast cancer, sometimes activating the above transcription 
factors [41-46]. For example, the induction of EMT in mammary epithelial cells through 
TGF-β and active Ras leads to the phosphorylation of Twist1 by p38 mitogen activated 
protein kinase (MAPK) and promotes invasiveness [47].  
When a loss in cell adhesion occurs through reprogramming to a mesenchymal-
like protein expression pattern, a change in polarity from apico-basal to front-rear is 
observed, which initiates invasion and motility with cytoskeleton remodeling [28, 48]. 
Specifically, activation of p38 signaling, especially of the p38γ isoform, through 
overexpression of RhoC GTPase has been found to be important in breast cancer cell 
motility and invasion [49, 50]. The induction of proteases, especially matrix 
metalloproteinases (MMPs), which degrade BM components, is also associated with 
EMT, and it has been demonstrated that levels of these enzymes are highest at the in 
situ stage prior to invasion [51-53]. It is believed that cancer cell motility is enhanced 
with these BM degrading enzymes as they may make channels through the BM and 
stroma allowing for movement. In breast cancer cells, p38α has been shown to be 
important in orchestrating motility and invasion as it mediates the expression of several 
MMPs [54]. Once free from the constraints of the BM, research suggests that cells 
within the stroma may enhance the aggressive behaviors of the cancer cells and 
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promote further motility and invasion [25, 55-57]. For example, secretion of IL-6 by 
adipocytes can stimulate invasion in breast cancer cells [25], and secretion of IL-4 by 
breast cancer cells can promote protease activity in macrophages [57]. A feedback loop 
may occur between carcinoma and stromal cells as carcinoma cells may create stroma 
with attributes associated with inflammation, and reactive stroma may then enhance 
aggressive traits within the carcinoma cells.  
Besides the need to lose cell-to-cell contacts and degrade the BM, breast tumor 
cells may also have to breach the outer layer of myoepithelial cells within the epithelium 
before even encountering the BM. Normal myoepithelial cells form a physical border 
between tumorigenic cells within the lumen and the underlying basement membrane. 
Studies suggest that myoepithelial cells can influence tumorigenic cells by blocking 
proliferation through promotion of growth arrest and apoptosis, and by blocking invasion 
through inhibition of angiogenesis and basement membrane degradation [58-60]. Thus, 
differentiated myoepithelial cells act as natural tumor suppressors, and it is not 
surprising then that gene expression profiles in myoepithelial cells surrounding a DCIS 
show significant differences from myoepithelial cells surrounding a healthy gland [61]. 
DCIS-associated myoepithelial cells exhibit overexpression of several chemokines, 
which boost proliferation, migration, and invasion of neighboring epithelial cells [61]. 
Moreover, the same cells show overexpression of enzymes implicated in degradation of 
the basement membrane and extracellular matrix, such as MMPs [61]. Interestingly, 
once a tumor is classified as invasive, the adjacent myoepithelial layer can no longer be 
found [60]. The mechanism behind this disappearance remains unknown but may be 
due to degradation of the myoepithelial cells by the very proteolytic enzymes they were 
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shown to overexpress. Mammary stem cells may also prevent myoepithelial 
differentiation or selective apoptosis may be responsible [62, 63]. How myoepithelial 
cells are eliminated needs to be deduced, but once they are gone, tumorigenic cells 
gain easier access to the basement membrane and stroma. Before their complete 
disappearance, myoepithelial cells play an important role in invasion influencing the 
tumor microenvironment through secretion of key proteins.  
 
Intravasation and Survival in the Circulation 
Intravasation occurs when invasive breast cancer cells enter the lumen of 
lymphatic or blood vessels. Although invasion of tumor cells into regional lymph nodes 
classifies a tumor as metastatic, it is believed that tumor cell dissemination via blood 
circulation is primarily responsible for distant metastasis [19]. Many aspects of EMT are 
believed to be important in intravasation as carcinoma cells are required to break 
through vessel walls. For instance, TGF-β signaling, a pathway known to induce EMT, 
has been shown to enhance breast cancer intravasation [64]. Outside of EMT, Wyckoff 
and colleagues have demonstrated that perivascular macrophages are associated with 
breast cancer intravasation implying the importance of the associated microenvironment 
[65]. Tumor cells may also initiate neoangiogenesis and create new blood vessels within 
their local microenvironment [18]. These vessels, unlike normal blood vessels, are 
characterized as being in a constant state of reconfiguration and are susceptible to 
leaks, which allows for easier intravasation [66, 67].  
Once successful intravasation occurs, breast carcinoma cells have the ability to 
widely travel throughout the blood circulation system and are termed circulating tumor 
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cells (CTCs). Recent advances have allowed for detection and characterization of CTCs 
in the bloodstream of patients [27, 68-70], and studies have revealed a correlation 
between the number of CTCs and patient survival [71-74]. In order for a successful 
metastasis to occur, CTCs must survive or evade certain stressors, such as anoikis 
caused by matrix detachment and detection by the immune system. The formation of 
large platelet-coated emboli has been shown to allow for survival by providing a shield 
from vascular turbulence and immune cells [75, 76].  
Even though invasion and migration might be considered effective processes, 
metastatic outgrowth is deemed quite inefficient as only 0.01% of CTCs are able to 
produce a single bone metastasis [77, 78]. Likewise, CTCs have been detected in 
disease-free breast cancer patients up to 22 years after treatment implicating that CTCs 
in the bloodstream are required, but not sufficient, for distant metastasis [21]. In 
addition, how long a CTC can persist in the bloodstream remains an unanswered 
question. As carcinoma cells at 20-30µm in diameter outsize the diameter of capillaries, 
it is expected that CTCs would become trapped quickly after intravasation, and this 
short time in circulation may allow for anoikis evasion by CTCs [18]. 
 
Arrest and Extravasation at Distant Sites 
  CTCs, if they survive circulation, do eventually arrest at a distant site and the 
most common metastatic organs for breast CTCs are the brain, bone, liver and lungs 
[18]. It is unknown whether this organotropism is due to the structure and size 
restrictions of capillaries in certain organs or an ability to selectively target to specific 
organs. It is confounding when carcinoma cells arrest in a distant organ that is 
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downstream of capillary beds whose diameters should have not allowed passage of 
CTCs. But, this does occur, and the plasticity of CTCs may be accountable and allow 
for entrapment at more distal sites. In contrast, CTCs may exhibit features that allow 
them to home to specific organs, implying that distinct adaptive programs may be 
developed for each metastatic site [20]. For instance, the expression of metadherin in 
breast cancer cells may allow for specific binding to the pulmonary vasculature [79]. 
Research has also found that chemokines may be involved in tissue tropism as breast 
cancer cells highly express chemokine receptor 4 (CXCR4), while its respective ligand, 
CXCL12, is highly expressed in lymph nodes, lung, liver and bone, but weakly 
expressed in other sites such as the kidney and skeletal muscle [80]. Several other 
studies in human breast cancer have described gene expression signatures associated 
with specific metastasis to bone, lung, liver and brain [81-84]. 
How CTCs become lodged at a distant site requires further research, but the 
process of CTCs invading through the luminal wall of a vessel and gaining access to the 
stromal tissue of a distant organ is known as extravasation [18]. Alternately, CTCs may 
become trapped and form a microcolony, and with additional growth, the microcolony 
may burst vessel walls and allow access to stromal tissue [85]. Although both 
mechanisms are possible, the following section will only focus on extravasation.  
It would seem logical that extravasation would be the reverse of intravasation, 
but the specific microenvironments at metastatic sites greatly differ from those 
surrounding the primary tumor site. As previously mentioned, blood vessels created by 
carcinoma cells within the primary tumor via neoangiogenesis are quite permeable and 
allow for easier intravasation. In contrast, blood vessels at the distant metastatic site are 
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expected to be normal and functional, and much less penetrable. This may partially be 
why nearly all CTCs arrested at a distant site die shortly after lodging [86, 87]. However, 
factors secreted by the primary tumor may create a pre-metastatic niche that aids in 
surmounting the vessel wall barrier by inducing vascular hyper-permeability. Secreted 
factors, such as Angptl4, MMP1 and MMP4, have been demonstrated to upset cell-to-
cell junctions in the pulmonary vasculature [67, 88]. Additionally, secretion of VEGF 
promotes extravasation of breast cancer cells through recruitment of inflammatory 
monocytes to pulmonary metastatic sites [89]. Taken together, the specific 
microenvironment present at possible distant sites plays a significant role in 
extravasation and metastasis formation. 
 
Survival and Metastatic Colonization 
Disseminated cancer cells are most likely poorly adapted to the 
microenvironment present at the metastatic site as the types of stromal cells and 
extracellular matrix components may differ from those present at the primary tumor site. 
Survival in the foreign microenvironment might be accomplished through establishment 
of the aforementioned pre-metastatic niche [90, 91]. This model proposes that cells from 
the primary tumor release factors prior to the arrival of CTCs that prime metastatic sites 
for colonization. These factors may include those previously mentioned that aid in 
organotropism and extravasation. Further evidence for a pre-metastatic niche has been 
illustrated through clustering of hematopoietic progenitor cells positive for the receptor 
VEGFR-1 to metastatic sites [91]. These hematopoietic progenitor cells work to modify 
the local microenvironment through release of MMP9, which may free the cancer cell 
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chemoattractant SDF-1. Survival may also be promoted through cell-autonomous 
programs and has been demonstrated in the activation of Src tyrosine kinase signaling 
in breast carcinoma cells disseminated to bone marrow. Although Src signaling was 
deemed dispensible for tissue homing, Src signaling provided survival and outgrowth 
signals for the tumor cells [92]. 
 Survival in a foreign microenvironment does not guarantee the formation of large, 
proliferating metastases (macrometastases) as breast cancer patients may go years or 
even decades without relapse after mastectomy [93]. In fact, disseminated cancer cells 
may undergo periods of dormancy, which may be due to a lack of growth signals or an 
incompatibility with the microenvironment [94, 95]. This quiescent state of mammary 
carcinoma cells has been shown to be dependent on a lack of integrin β1 signaling at 
distant sites [96-98]. Additionally, cell-nonautonomous programs may be necessary for 
metastatic proliferation. Breast cancer cells may stimulate the mobilization and 
recruitment of bone marrow-derived cells to a metastatic site through secretion of 
factors, such as osteopontin and SDF-1, and they may trigger outgrowth [99, 100]. 
Conversely, proliferation of cancer cells may occur freely in a metastatic site, but a net 
gain in size may not be seen and may be due to a high rate of apoptosis or a failure in 
neoangiogenesis [95].  
 Ongoing research has delineated many of the steps and mechanisms involved in 
breast cancer metastasis as demonstrated in the previous sections, but much remains 
to be discovered. Hopefully, ongoing research will help to make a diagnosis of 




1-3. Breast Cancer and the Cancer Stem Cell Hypothesis 
The cancer stem cell (CSC) hypothesis postulates that malignant tumors are 
initiated and maintained by a subpopulation of neoplastic cells that possess similar 
properties to normal adult stem cells. In order to qualify as a CSC, three functional 
characteristics must be exhibited [101, 102]. First, CSCs must have the ability to initiate 
a phenocopy of the primary tumor in immunocompromised or syngeneic mice, which 
explains why CSCs are interchangeably referred to as tumor-initiating cells. Second, a 
capacity for self-renewal must be demonstrated in secondary mice.  Cells from newly 
formed tumors initiated by potential CSCs, when serially transplanted, must form 
additional tumors that recapitulate the primary tumor. Third, CSCs must have the 
capacity to form tumors that contain the original heterogeneity of cell types found in the 
bulk of the primary tumor from which they were derived. This characteristic shows a 
capacity for pluripotency as CSCs must be able to differentiate into a population of non-
self-renewing cells, which may constitute the majority of a tumor. 
 Two prominent theories aim to describe the origin of CSCs [103]. One model 
builds on the linear progression of cancer described earlier where cancers are believed 
to develop through an accumulation of mutations over a longer period of time. As adult 
stem cells are long-lived and have a high proliferative capacity, they have the potential 
to acquire the numerous mutations that lead to a malignant state. Indirect evidence 
supporting this model has been demonstrated in vitro as adult stem cells were shown to 
spontaneously transform into tumorigenic stem cells [104-108]. Alternately, the other 
model proposes that CSCs result from mutations in lineage-committed cells, which lead 
to dedifferentiation and the acquisition of self-renewal capacity. Takahashi and 
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colleagues showed that pluripotent stem cells could be induced in differentiated cells 
through expression of a small subset of transcription factors [109]. Although both 
models are possible, they each are consistent with the concept of the CSC hypothesis 
in that tumorigenic cells exhibit stem-like properties in propagating a malignancy.    
The profound expansion and proliferation of the mammary gland during puberty 
and pregnancy implies the existence of adult breast stem cells. Indeed, early studies in 
mice demonstrated that an entire mammary gland could be generated in vivo in a 
cleared fat pad from serially transplanted portions of mammary epithelium [110-113]. 
Building on this work, other researchers have found that a functional mammary gland 
could be produced from transplantation of a single cell in mice [114, 115]. Kuperwasser 
and colleagues extended these studies to a human relevance through development of a 
xenograft model in which functional mammary glands from human epithelial cells were 
generated in mouse fat pads “humanized” by injections with irradiated human fibroblasts 
[116]. The use of these in vivo transplant assays has allowed for the identification of 
breast stem cell markers. For example, human breast stem cells have found to be 
enriched in CD49fhiEpCAM- fractions and in fractions positive for Aldehyde 
Dehydrogenase 1 (ALDH1+) activity [117-119].  
Evidence for the existence of mammary stem cells has been accumulating since 
the 1950s; however, the identification of human breast CSCs has been a more recent 
event. Al-Hajj and colleagues were the first in 2003 to show that a minority of breast 
cancer cells had the ability to form new tumors when serially transplanted in NOD/SCID 
mice, and these breast CSCs were identified and isolated as being CD44+/CD24-/low  
[120]. In another study, an invasiveness gene expression profile was generated for 
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CD44+/CD24-/low breast CSCs compared to cells of normal breast epithelium, and 
researchers found that this profile predicted shorter metastasis-free survival in patients 
[121]. The CD44+/CD24-/low profile has also been associated with CSCs in other solid 
tumors, including gastric and prostate [122, 123]. However, the cell surface profile of 
breast CSCs has been extended to include ESA, ALDH1, and CD133, amongst others 
[103, 118]. Additionally, the development of an in vitro cultivation system, known as the 
mammosphere assay, has shown that the ability to form non-adherent spheres in 
culture is a property of breast stem cells and CSCs and allows for enrichment of these 
populations [118, 124-126]. More, established breast cancer cell lines have been shown 
to contain subpopulations of CSCs identified by ALDH1 or CD44+/CD24-/low [126-128]. In 
all, CSCs expressing these markers have been found to display enhanced invasive and 
metastatic capabilities and to associate with poor clinical outcome in breast cancer [118, 
125-127, 129]. Recent studies also suggest that CSCs may be more resistant to 
radiation and chemotherapy implying that these treatments mainly target non-CSCs, 
while CSCs may remain behind to proliferate and repopulate the tumor [130-132].  
Recently, an interesting link between CSCs and EMT has been put forth. Two 
independent studies have found that induction of EMT in differentiated human 
mammary epithelial cells increases the number of cells that express surface stem cell 
markers and that form mammospheres [133, 134]. It was also observed that stem-like 
cells isolated from normal human mammary glands and breast carcinomas expressed 
EMT markers at higher levels when compared to non-stem cells [133]. When EMT was 
induced in transformed human mammary epithelial cells, a CSC phenotype was 
induced as these cells formed mammospheres and tumors more efficiently. In addition, 
 
 18 
the acquisition of a stem cell-like gene expression signature has been associated with 
poor prognosis and high grade estrogen receptor negative (ER-) breast cancers, often 
of the aggressive basal-like subtype [102]. As previously mentioned, a mesenchymal 
phenotype was found to associate in basal-like tumors, signifying that the relationship 
between mesenchymal differentiation and metastatic capabilities may be extended to 
include a stem cell-like gene expression [36]. These findings revealed for the first time a 
direct relationship between EMT and CSC properties, and imply that CSCs may play an 
important role in breast cancer metastasis.  
It is not surprising  that many signaling pathways, such as Wnt, Hedgehog and 
Notch, which are important in the regulation of EMT have been implicated in CSCs [101, 
103]. Specifically, in the normal mouse mammary gland, Notch was found to regulate 
the expansion of stem cells and differentiation to a luminal lineage establishing a role for 
Notch in normal breast development [135, 136]. Many studies have implicated a 
correlation between the expression of Notch receptors and ligands in breast cancer 
progression, which associates with poor prognosis and survival [137-144]. Research 
utilizing pre-clinical models of DCIS, Notch signaling was shown to have a role in DCIS 
acini growth and mammosphere formation through treatment with the Notch inhibitor 
DAPT [145]. In a study of breast CSCs, Notch4 signaling activity was shown to be 
increased when compared to differentiated cells and that inhibition of Notch4 reduced 
stem cell activity and tumor formation [146]. A number of recent studies investigating 
Notch1 have established its role in breast CSCs as inhibition of Notch1 through several 
methods reduces CSC populations, tumor incidence and the formation of metastasis 
[147-152]. In further support, knockdown of nicastrin, a component of the γ-secretase 
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protein complex that is responsible for the release of the activated intracellular domain 
of Notch1, in breast cancer cells led to a decrease in CSCs and invasion accompanied 
by a morphological change to an epithelial-like phenotype in vitro and decreased 
tumorigenicity in vivo [153]. Mao and colleagues found that Notch1 may play a critical 
role in the resistance of CSCs to chemotherapy as knockdown of Notch1 in breast cells 
treated with paclitaxel decreased CSC populations and tumor growth [154].  Further 
research delineating the signaling pathways involved in CSCs will aid in drug discovery 
and hopefully help in targeting the cells that may be responsible for a good portion of 
tumor propagation.  
1-4. The Tumorigenic Role of EZH2 
Overexpression of the epigenetic regulator Enhancer of Zeste Homolog 2 (EZH2) 
in a wide range of malignancies has been established in cancer research. EZH2 was 
first associated with aggressive and metastatic prostate cancer through analyses of 
gene expression in human tumor microarrays [155]. Through similar microarray profiling 
and other studies, EZH2 expression was found to strongly correlate with breast cancer 
aggressiveness acting as an independent predictor of recurrence and survival [156-
159]. EZH2 was also found increased in histologically normal breast epithelium with a 
higher risk of developing cancer, indicating that EZH2 may prove as a valuable marker 
for detecting preneoplastic lesions [160, 161]. Elevated EZH2 expression has since 
been described in other types of cancers: bladder [162-164], liver [165], colon [166-
168], lung [169], gastric [170], enodometrial [157], skin [157, 171], lymphoma [172-175], 
pancreatic [176], Ewing’s sarcoma [177, 178], and myeloma [179]. In all reported cancer 
studies, the common discovery is that EZH2 expression is increased in cancer 
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compared to normal tissues, being the highest in the most advanced stages of cancer, 
and correlates with poor prognosis in patients.  
  
Polycomb-Mediated Epigenetic Silencing 
EZH2 is classified as a member of the Polycomb-group (PcG) family of proteins. 
PcG proteins were initially identified as regulators of body patterning by silencing 
homoeotic (Hox) genes in Drosophila melanogaster [180-182]. Upon mutation of PcG 
genes, flies displayed defects in body segmentation in the anterior-posterior axis that 
were attributed to the expression of Hox genes outside their normal spatial regions. 
Repressive functions of PcG proteins have been conserved through vertebrates as 
several PcG mutants exhibit skeletal malformations [183-186]. In addition, the crucial 
role of PcG proteins in mammalian development is emphasized by studies showing that 
deletion of some genes encoding for PcG proteins leads to early embryonic lethality in 
mice [187-191]. Our current understanding of the role PcG proteins play in transcription 
regulation has expanded to include genes outside the Hox family. Through numerous 
genome wide chromatin immunoprecipitation (ChIP) studies and other approaches, PcG 
proteins have been found to accumulate at hundreds of target genes in Drosophila [192-
197] and mammalian cells [198-202]. These reports indicate that PcG proteins in flies 
and vertebrates regulate approximately 1.3% and 3-4% of genes, respectively, and that 
the most prevalent target genes are transcription factors. Interestingly, several studies 
have demonstrated differences in PcG protein binding profiles signifying that PcG gene 
regulation can vary in different cell types and at different stages of development [193, 
199, 202]. With the wide spectrum of target genes identified thus far, it is not surprising 
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that PcG proteins have emerged as regulators of key processes such as multicellular 
development, cell fate determination and tumor formation [203-205]. 
At the molecular level, PcG proteins are mainly divided into two distinct groups 
dependent on their formation of multimeric complexes, termed Polycomb Repressive 
Complex 1 (PRC1) and PRC2 (Figure 1-2) [203, 205-208]. PRC2, which is conserved 
from Drosophila to mammals, consists of three core mammalian members that are 
required for catalytic activity: EZH2, Suppressor of Zeste 12 (Suz12), and Embryonic 
Ectoderm Development (EED). Other proteins have been shown to transiently interact 
with PRC2 include RbAp46/48 [209-211], AEBP2 [211-213], JARID2 [214-218], the 
mammalian orthologs of Drosophila PCL proteins (PHF1, MTF2, & PHF19) [214, 219-
223], SIRT1 [224], and EPC1 [121]. Although these factors are not required for PRC2 
enzymatic activity in vitro, they generally confer modulating and/or recruiting functions 
as they have been shown to be necessary for optimum PRC2 transcriptional repression. 
The core composition of PRC1 is much more variable and contains one subunit of the 
CBX, RING1, SCML, PHC, and PCGF paralog protein groups, with many of these 
paralogs exhibiting overlapping and redundant functions [132, 203-205, 225]. 
Altogether, multiple versions of PRC1 and PRC2 exist in mammalian systems, and the 
differing configurations may confer distinct functions.  
Functionally, PRC2 is responsible for initiating gene repression and occurs when 
the catalytically active member EZH2 methylates histone H3 at lysine 27 [126, 209, 211, 
226]. Even though EZH2 is capable of adding three methyl groups to the ε-amino group 
of the lysine side chain, the trimethylated form, H3K27me3, is predominant and 
considered to convey gene repression as its genome-wide distribution coincides with 
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PcG complexes. Furthermore, the C-terminal cysteine-rich and SET domains of EZH2 
were shown to be required for this catalytic activity. Studies suggest that once 
methylated, the H3K27me3 mark is specifically recognized by the chromodomain of a 
CBX protein within PRC1 [227]. The recruitment of PRC1 leads to monoubiquitination of 
histone H2A on lysine 119 (H2AK119ub) by the E3 ubiquitin ligases RING1 [228-230]. 
This monoubiquitination is believed to block binding of transcription factors, inhibit 
transcription initiation by RNA polymerase II and compact chromatin [231, 232]. 
Although it is generally accepted that PRC1 functions downstream of PRC2 as outlined 
above, this may not always be the case. Studies have demonstrated that some genes 
targeted by PRC2 lack PRC1 or H2AK119ub, and conversely, some genes targeted by 
PRC1 do so in the absence of PRC2 [233-235]. Generally, though, both of the post-
translational modifications rendered by PRC1 and PRC2 are often required for gene 
repression. 
Recent studies in human cells have demonstrated physical and functional links 
between PcG repression and other epigenetic modifications. Vire and colleagues found 
PRC2 regulates DNA methylation as EZH2 co-immunoprecipitated with three DNA 
methyltransferases (DNMTs), which resulted in recruitment of DNMTs to PRC2 target 
genes and subsequent methylation [236]. Additionally, BMI1and two CBX paralogs, 
members of PRC1, have been shown to interact with DNMTs [237-239]. It is estimated 
that approximately 47% of genes regulated by DNMT3B are also bound by PRC1 and 
PRC2 in colon cancer cells [240]. The link between EZH2 and DNA methylation has 
been expanded as PRC2 and H3K27me3 have been found at gene promoters 
containing aberrant CpG island hypermethylation in cancer cells [241-243]. These 
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hypermethylated gene promoters were seen to correlate with sites displaying 
H3K27me3 during normal development suggesting that these genes may be tagged to 
undergo hypermethylation during transformation. In support, another study by Ku and 
colleagues showed that >97% of genes bound by EZH2 in embryonic stem cells 
associated with CG-rich DNA sequences or CpG islands [233]. In relation to other 
histone methylating marks, researchers have found that the H3K4 demethylase RBP2 
associates with PRC2 at a number of PcG target genes in mouse embryonic stem cells 
[210]. As trimethylation of H3K4 is normally associated with active gene transcription, 
this mechanism suggests a coordinated regulation of H3K4 demethylation and H3K27 
trimethylation during development. Lastly, histone deacteylase (HDAC) activity has 
been shown to be required for mediating gene repression by PcG proteins, and EED 
directly interacts with HDAC1 [155, 156, 244, 245]. 
In order to better understand how PcG proteins regulate gene expression, a 
better comprehension of how PcG complexes are recruited to specific target genes is 
required. In Drosophila, PcG proteins are recruited to specific DNA sequences 
upstream of target genes, which are defined as Polycomb Repressive Elements [205, 
207]. These elements contain several hundred base pairs, can be distally located away 
from the transcription start sites of target genes and contain DNA-binding consensus 
sites for transcription factors [246, 247]. Until recently, truly similar motifs had yet to be 
identified in vertebrates. A 3 kb murine PRE, termed PRE-kr, was found by Sing and 
colleagues to regulate expression of the mouse MafB/Kreisler gene [234]. PRE-kr 
contains a palindromic double PHO-binding site, which is not present in the human 
PRE-kr sequence. Interestingly, PRC1 bound the PRE-kr with higher affinity than PRC2, 
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which indicated that PRC1 gene recruitment may not be completely dependent upon 
PRC2. Even more recently, a potential 1.8 kb PRE has been identified in human 
embryonic stem cells [248]. Located between the HOXD11 and HOXD12 loci, the region 
contains binding sites for YY1, a transcriptional regulator whose knockdown removes 
EZH2 and H3K27me3 from target genes in mouse myoblasts [248, 249]. YY1, in 
addition to PRC1 and PRC2, was found recruited to this PRE.  
Recruitment of PcG complexes may also occur through intermediary molecules. 
For instance, DNA-binding protein JARID2 has been demonstrated to form a stable 
complex with PRC2 and was shown to be required for recruitment of PRC2 to target 
genes [217]. The phosphatase NIPP1 also has been found to complex with PRC2 on 
chromatin and they silence a common set of genes [250]. NIPP1 knockdown results in 
the dissociation of EZH2 from some target genes whereas NIPP1 overexpression 
causes a redistribution of EZH2 between target genes [251]. In another example, Gupta 
and colleagues found that overexpression of the long noncoding RNA HOTAIR in 
epithelial cancer cells retargeted PRC2 genome-wide to specific targets, silencing 
metastasis suppressor genes [252]. Expression of HOTAIR was found to be associated 
with aggressive breast cancer and the authors observed that loss of HOTAIR inhibited 
cancer invasiveness, suggesting that lincRNAs may have a modulating role in recruiting 
PRC2 to genes involved in cancer progression. In another study, HOTAIR was found to 
target PRC2 to the human HOXD cluster as its depletion led to decreased H3K27me3 
and the re-expression of genes in this locus [253]. Lastly, leukemic fusion proteins PML-
RARα, PLZF-RARα and TMPRSS2-ERG have the capability to recruit PcG proteins to 
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specific target loci implying oncogenes may play a role in PcG-related carcinogenesis 
[254-256].  
 
EZH2 and Cancer 
As previously mentioned, EZH2 is overexpressed and associated with poor 
prognosis and metastasis in numerous types of cancer. EZH2 has been established as 
an oncogene as its overexpression in cancer cells in vitro leads to increased cell 
proliferation, invasion and colony formation [155, 156, 257, 258]. Additionally, 
overexpression of EZH2 induces tumor growth in xenograft mouse models [179, 258, 
259]. Conversely, when EZH2 is downregulated in cancer cells, a concomitant decrease 
in cell proliferation in vitro and in tumor growth in vivo is observed [155, 179, 259-261].  
Multiple studies have indicated that overexpression of EZH2 in cancer can occur 
at various levels. At the transcriptional level, Bracken and colleagues have revealed that 
the pRB-E2F pathway regulates the expression of EZH2 and EED through direct 
binding of E2F transcriptions factors to EZH2 and EED promoters, which leads to 
activation and proliferation [257]. In Ewing’s sarcoma, the EWS/FLI1 fusion protein 
binds to the EZH2 promoter and induces expression in tumor cells and mesenchymal 
stem cells [178]. Loss of the SNF5 tumor suppressor in prostate cancer leads to 
increased expression of EZH2 and activation of stem cell-associated gene expression 
signatures [262]. Additionally, micro-RNAs have been shown to regulate EZH2 levels as 
loss of miR-26a and miR-101 in lymphoma and prostate cancer cells, respectively, 
leads to EZH2 overexpression [263-265]. Recent work in lymphoma has also identified 
a heterozygous missense mutation in EZH2 at amino acid Y641, within the SET domain 
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[266, 267]. Wild type EZH2 has a high catalytic activity for monomethylation of H3K27, 
whereas Y641 mutants have enhanced catalytic activity for di- and trimethylation of 
H3K27. Therefore, the combination of the two catalytic activities of mutant and wild type 
EZH2 resulted in increased gene repression through H3K27me3 in a mechanism 
equivalent to EZH2 overexpression.  
EZH2 plays a multi-faceted role in cancer through regulation of a plethora of 
genes, many of which have been implicated in development of metastasis. For 
example, Cao and colleagues have found in prostate cancer cells that EZH2 promotes 
EMT by repression of E-cadherin expression through interaction with Snail1, and this 
influence on E-cadherin has since been demonstrated in many other types of cancer 
cells [268]. In addition, EZH2 has been found in breast cancer cells to directly repress 
ADAMTS1, a gene encoding for a metallopeptidase which degrades proteins in the 
extracellular matrix disrupting cell adhesion and promoting migration [269]. EZH2 has 
also been found to be a direct driver of tumor initiation and metastasis in prostate 
cancer cells through silencing of DAB2IP, a RasGap gene known to regulate Ras and 
NF-κB [270, 271]. Moreover, repression of FOXC1 by EZH2 in breast cancer cells was 
seen to inhibit differentiation, whereas stable overexpression of FOXC1 protein reduced 
migration and invasion in vitro and metastasis in vivo [272]. Ren and colleagues have 
reported that EZH2 directly represses the metastasis suppressor RKIP in breast and 
prostate cancer cells leading to increased invasion through an interaction with Snail1 
[273]. Likewise, in hepatocarcinoma cells, EZH2 has been found to epigenetically 
repress several micro-RNAs characterized as tumor suppressors for their anti-tumor or 
anti-metastatic established roles [274]. In addition, EZH2 has been implicated in 
 
 27 
promoting tumor angiogenesis and ovarian cancer growth in vivo as VEGF-stimulated 
overexpression of EZH2 leads to the repression of VASH1, a negative regulator of 
angiogenesis [275]. Our laboratory has discovered a novel link between EZH2 and DNA 
repair mechanisms as overexpression of EZH2 in breast cells impaired the formation of 
RAD51 repair foci at sites of DNA damage leading to decreased cell survival [276]. In 
another recent study, EZH2 expression-mediated downregulation of RAD51 led to 
RAF1 gene amplification and an expansion in breast tumor-initiating cells, linking EZH2 
to regulation of CSCs [277].   Taken together, these studies confirm the essential roles 
EZH2 plays in tumor progression and suggest that blocking EZH2 expression or activity 
may have therapeutic implications.  
Although primarily known as a gene silencer, evidence has emerged indicating 
EZH2 in activating functions. In genome-wide mapping ChIP experiments, 10-20% of 
PcG target genes were found actively transcribed in embryonic stem cells, and 2% of 
genes bound by PcG proteins were also bound by RNA Polymerase II [200, 201]. 
Indeed, EZH2 has been demonstrated to be required in the expression of several genes 
important in cell cycle regulation providing a proliferative advantage [257]. In another 
study using breast cancer cells, EZH2 was demonstrated to directly activate the 
transcription of c-myc and Cyclin D1, genes commonly targeted by Wnt signaling, 
through interaction with Estrogen Receptor α and β-catenin [278]. This activity was 
found to be independent of the SET domain and instead required the two N-terminal 
homology domains of EZH2. Another study utilizing glioma CSCs and ChIP experiments 
also revealed that c-myc is a positively regulated direct target of EZH2 as c-myc 
expression was strongly repressed upon EZH2 downregulation [279]. Su and 
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colleagues have reported the existence of cytosolic EZH2, which still forms a complex 
with SUZ12 and EED [280]. They found EZH2 to regulate Actin polymerization, and 
suggested post-translational lysine methylation by EZH2 as a novel function in signal 
transduction. In further support, Lee and colleagues demonstrated that EZH2 physically 
interacts with RelA and RelB proteins to promote the expression of NF-κB target genes 
in basal-like breast cancer cells, independent of the SET domain [281]. Moreover, EZH2 
has been indicated to activate the transcription of AXL, a gene encoding for a receptor 
tyrosine kinase implicated in mesenchymal development, in a methylation independent 
manner in glioma cells [282]. Another recent study demonstrated in prostate cancer 
cells that EZH2 binding to transcriptionally active gene sites occurred independent of 
PRC2 complex members and H3K27me3 [283]. Although independent of its 
H3K27me3, the authors found the SET domain to be required for gene activation. 
Taken together, these studies establish context-specific, non-repressive roles for EZH2, 
and promote the need for further research into understanding all functions of EZH2.  
 
*    *    * 
 
It is well known that EZH2 is vital in a number of key cellular processes, such as 
embryonic and adult stem cell maintenance and tumor progression. Although an 
association between EZH2 and breast cancer metastasis has been established, a 
causal relationship has not. The over-arching hypothesis of this thesis is that EZH2 
overexpression in cancer cells is required for breast cancer metastasis. In Chapter 2, 
the regulation of EZH2 on key steps in metastasis, such as EMT, invasion and motility, 
and the underlying mechanisms will be more thoroughly examined in vitro. Using a 
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xenograft mouse model system, we will directly address whether knockdown of EZH2 in 
breast cancer cells affects metastatic burden in vivo. In Chapter 3, the regulation of 
EZH2 on CSCs, which are implicated in metastasis, will be studied in both tumorigenic 
and malignant breast cells. Do the levels of EZH2 influence the numbers and 
tumorigenicity of CSCs? And, if so, what signaling pathways are essential for this 



















Figure 1-1 The continuum of breast cancer progression and the metastatic 
cascade. 
(A) Breast cancer is a believed to develop along a continuum. The normal breast 
terminal ductal lobular unit (TDLU) contains lobules and ducts that consist of a bilayered 
epithelium of luminal and myoepithelial cells. Atypical ductal hyperplasia (ADH) is a 
premalignant lesion characterized by abnormal cell layers within the duct or lobule. ADH 
is thought to be the precursor of ductal carcinoma in situ (DCIS), which is a non-
invasive lesion that contains abnormal cells still confined within the duct. With each 
stage, the risk of developing malignant or invasive breast cancer (IBC) increases. DCIS 
may give rise to IBC (indicated by a blue star adjacent to a DCIS lesion), although how 
to predict which lesions will progress is still unknown. Once cells have invaded through 
the surrounding basement membrane into the stroma, the risk for developing metastasis 
significantly increases. The lymph nodes are the primary site for breast cancer 
metastasis (indicated by a blue star). (B) A schematic of breast cancer progression is 
shown. The transformation of breast epithelial cells to metastatic breast cancer is an 
accumulation of epigenetic and genetic changes and aberrant interactions within the 
microenvironment. During this multistage process, control of proliferation, survival, 
differentiation and migration become deregulated, and aberrant tumor–stromal cell 
interactions facilitate this process. To form metastases, cells must invade through the 
basement membrane, enter the vasculature through intravasation, survive in the 
absence of adhesion in the circulatory system, exit the vasculature through 
extravasation, and establish a new tumor in a foreign microenvironment.  
(From Vargo-Gogola and Rosen, Nature Reviews Cancer, 2007) 
 
 






Figure 1-2 Polycomb Repressive Complexes 1 and 2 (PRC1 & PRC2) coordinately 
work together to repress gene expression.  
(A) PcG proteins are mainly divided into two distinct groups dependent on their 
formation of the multimeric complexes PRC1 and PRC2. The methyltransferase EZH2 
is the catalytic core member of PRC2, which trimethylates histone H3 at lysine 27 
utilizing its SET domain (H3K27me3) in association with other members EED and 
SUZ12. The core composition of PRC1 is much more variable and contains one subunit 
of the CBX, RING1, SCML, PHC, and PCGF paralog protein groups. It is believed that 
PRC1 is recruited to the H3K27me3 mark through the affinity of chromodomains in CBX 
proteins. PRC1 recruitment leads to the monoubiquitination of histone H2A on lysine 
119 by the RING1 proteins, which is thought to block the binding of transcription factors 
and inhibit transcription initiation by RNA Polymerase II resulting in transcriptional 
repression. 
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EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility 
and metastasis 
The contents of following chapter have been published in Breast Cancer Research and 
Treatment (DOI: 10.1007/s10549-013-2498-x) under the above title by Heather M. 
Moore, Maria E. Gonzalez, Kathy A. Toy, Ashley Cimino-Mathews, Pedram Argani and 
Celina G. Kleer. 
2-1. Abstract 
EZH2 is a Polycomb group protein that exerts oncogenic functions in breast 
cancer, where its overexpression is associated with metastatic disease. While it 
reportedly acts a transcriptional repressor through trimethylation of histone H3 at lysine 
27, EZH2 may exhibit context-dependent activating functions. Despite associations with 
worse outcome and metastasis in breast cancer, a functional role of EZH2 in breast 
cancer metastasis in vivo has not been demonstrated. Furthermore, whether EZH2 
regulates cancer cell phenotype and motility are unknown. In this study, we discovered 
that knockdown of EZH2 induces a phenotypic reprograming from mesenchymal to 
epithelial, reduces motility, and blocks invasion in breast cancer cells. In vivo, EZH2 
downregulation in MDA-MB-231 cells decreases spontaneous metastasis to the lungs. 
We uncover an unexpected role of EZH2 in inducing the p38 mitogen-activated protein 




metastasis. In breast cancer cells EZH2 binds to phosphorylated-p38 (p-p38) in 
association with other core members of the Polycomb Repressive Complex 2 (PRC2), 
EED and SUZ12, and EZH2 overexpression leads to increased levels of p-p38 and of 
activated, downstream pathway proteins. The effect on p-p38 was confirmed in vivo 
where it correlated with decreased spontaneous metastasis. In clinical specimens of 
matched primary and invasive breast carcinomas, we found that EZH2 expression was 
upregulated in 100% of the metastases, and that EZH2 and p-p38 were coexpressed in 
63% of cases, consistent with the functional results. Together our findings reveal a new 
mechanism by which EZH2 functions in breast cancer, and provide direct evidence that 
EZH2 inhibition reduces breast cancer metastasis in vivo.  
2-2. Introduction 
Breast cancer is the 2nd most common cause of cancer-related deaths for women 
in the United States [1]. Despite advances in breast cancer detection and treatment 
strategies, metastatic breast cancer is essentially incurable and the 5 year survival rate 
for women diagnosed with distant metastatic disease is only 23% [2]. The degree of 
breast cancer cell differentiation directly impacts its metastatic ability; the more 
undifferentiated the primary invasive carcinoma, the greater likelihood to develop 
metastasis [3]. Thus, it is not surprising that dysregulation of cell type identity and 
differentiation programs directly impact breast cancer metastasis. 
Polycomb group proteins are major regulators of cellular memory that function in 
multimeric complexes to regulate the expression of specific genes, mainly through 
transcriptional repression. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core 




trimethylation of histone H3 lysine27 (H3K27me3) [4-6]. Although primarily functioning 
in gene repression, EZH2 has been shown to exhibit gene activating functions, at times 
through mechanisms independent of its histone methyltransferase activity [7-13]. EZH2 
is highly expressed in a wide range of human cancers and has been shown to mediate 
the expression of target genes involved in tumorigenesis, including cell cycle regulation 
and proliferation, stem cell maintenance, cell differentiation, and neoplastic cell 
transformation [14-16]. EZH2 protein is overexpressed in 55% of invasive breast 
carcinomas, and is significantly associated with poorly differentiated, estrogen receptor 
negative (ER-) tumors. We have demonstrated that EZH2 is an independent prognostic 
biomarker in breast cancer as women with tumors expressing high EZH2 have worse 
disease free and overall survival than women with tumors expressing low EZH2 [17-21]. 
Despite these associations, direct demonstration that EZH2 downregulation decreases 
breast cancer metastasis is lacking.  
The p38 mitogen-activated protein kinase (MAPK) signaling pathway plays a 
complex and key role in cancer progression by translating extracellular signals into 
cellular responses through phosphorylation of specific serine and threonine residues of 
downstream effector proteins, especially transcription factors and protein kinases. Four 
p38 isoforms have been identified, whose implications in tumorigenesis may depend on 
cell context and tumor type [22, 23]. Once activated, p38 has been associated with 
regulation of the epithelial-to-mesenchymal transition (EMT), invasion and motility of 
cancer cells, all cellular processes that are crucial to metastasis [22, 23]. Recently, 
elevated p38γ expression was shown to be associated with a lower overall survival of 




In this study, we demonstrate a previously undescribed function of EZH2: its role 
in cancer cell motility and cell phenotype. EZH2 knockdown in breast cancer cells 
induces a mesenchymal-to-epithelial transition (MET), decreases cancer cell motility 
and the speed of movement. We provide first evidence that EZH2 knockdown in breast 
cancer cells reduces lung metastasis in vivo. Mechanistically, EZH2 binds to 
phosphorylated p38 (p-p38) and upregulates p38 downstream signaling, while EZH2 
inhibition in breast cancer cells decreases p-p38 binding, expression, and downstream 
signaling. The relevance of our in vivo and in vitro studies to human breast cancer is 
highlighted by the finding that human breast cancer distant metastases express high 
levels of EZH2 and p-p38.  Taken together, this study identifies a novel function of 
EZH2 in controlling p-p38 activity, breast cancer cell motility, invasion and metastasis.  
2-3. Materials and Methods 
Cell culture 
Breast cancer cell lines MDA-MB-231 and MCF7 and mammary epithelial cell 
line MCF10A were obtained from the American Type Culture Collection (Manassas, 
VA). All obtained cell lines were grown under recommended conditions. The SUM149 
breast cancer cell line was obtained from the S. Ethier laboratory (Karmanos Cancer 
Institute, Detroit, MI) and cultured as previously reported [25].  
The primary breast cancer cells (designated as Primary Tumor in text and 
figures) were derived from a donated tissue from a consenting 36 years old patient in 
accordance with a protocol approved by the Institutional Review Board at the University 
of Michigan (IRB#2002-227). The tumor was 2.4cm in size and classified as a Grade 3, 




operating room and immediately processed in the laboratory. A portion of the tumor was 
formalin fixed and paraffin embedded for staining with hematoxylin and eosin (H&E) and 
immunohistochemical staining with anti-EZH2 (Cell Signaling, #5246, 1:100); see the 
Immunohistochemistry section for a detailed staining protocol. Another portion was 
processed a to single cell suspension as previously described [26]. Briefly, the tumor 
specimen was manually minced and then dissociated in a collagenase-hyaluronidase 
solution (StemCell Technologies, #07912). Next, red blood cells were lysed with RBC 
Lysis Solution (Qiagen, #158902). For further purification, the tissue was treated with 
Trypsin-EDTA (GIBCO, #25200-056), then DNase1 (StemCell Technologies, #07900) 
and finally filtered through a 40µm cell strainer. Cells were then cultured in Mammary 
Epithelial Cell Medium (ScienCell, #7611) completed with Mammary Epithelial Cell 
Growth Supplement and penicillin-streptomycin (ScienCell, #7652 and #0503).  
EZH2 knockdown using stable short-hairpin interfering RNA in lentivirus was 
completed as previously reported [20]. For targeting EZH2 (NM_152998, NCBI), the 
shRNA oligo ID# V2LHS_17507 was used and corresponded to #RHS4430-99139126 
from Open Biosystems (Hunstville, AL); this oligo was cloned into a pLKO.1-Puro 
vector. The shRNA containing plasmid was packaged into lentiviral particles at the 
Vector Core at the University of Michigan. A lentivirus containing a plasmid encoding a 
scrambled shRNA oligo was used as a control. Cells were transduced and selected for 
antibiotic resistance with puromycin (Sigma-Aldrich, #P9620). EZH2 knockdown was 
also achieved using 3-Deazaneplanocin A (Cayman Chemical, #13828) at 1µM for 5 
days treating every other day. As previously reported, transient EZH2 overexpression 




48 hours, kind gift of A. Chinnaiyan [27, 28]. The p-p38 inhibitors, SB203580 (Cell 
Signaling, #5633) or SB202190 (abcam, #120638) were used at 10 or 20µM for 48 
hours.  
 
Western blotting and immunoprecipitations 
Cells were lysed in RIPA lysis buffer with added protease and phosphatase 
inhibitors (Thermo Scientific, #89900, #78410 & #78420) and Western blot analyses 
were carried out using 50μg of whole cell extract. Samples were boiled in laemmli 
sample buffer, separated by SDS-PAGE gels and transferred onto PVDF membranes. 
Membranes were blocked and incubated with primary antibodies in 3% BSA (Sigma-
Aldrich, #A3059) in TBS-T (Bio-Rad, #161-0372, with 0.05% Tween20) at 4°C 
overnight. Protein signals were visualized via chemiluminescence as described by 
manufacturer (Thermo Scientific, #32106). β-Actin-HRP (Santa Cruz, #47778) was used 
to confirm equal loading. The following antibodies from Cell Signaling antibodies: rabbit 
monoclonals anti-EZH2 (#5246), anti-E-cadherin (#3195), anti-SUZ12 (#3737), anti-
p38β (#2339), anti-p38δ (#2308), anti-MAPKAPK-2 (#3042), anti-Snail1 (#3879); rabbit 
polyclonals anti-p38 (#9212), anti-p38α (#9218), anti-p38γ (#2307), anti-phospho-
HSP27 (Ser82, #2401), anti-phospho-MAPKAPK-2 ( #3007); mouse monoclonals anti-
Snail1 (#3895) and anti-HSP27 (#2402). From Abcam: rabbit monoclonal anti-
Cytokeratin-18 (#32118), rabbit polyclonal anti-EED (#4469) and mouse monoclonal 
anti-trimethyl-HistoneH3 ( #6002). Additionally: rabbit polyclonal anti-ACTIVE®-p38 





Immunoprecipitations (IPs) were conducted following protocol instructions 
(Sigma-Aldrich, #IP50). Protein was extracted from 70% confluent cells with provided IP 
buffer and added protease and phosphatase inhibitors (Thermo Scientific, #78410 & 
#78420). Whole protein extracts were precleared with provided Protein G agarose 
beads for 3 hours and then incubated with antibody (anti-normal mouse IgG [Santa 
Cruz, #2025], anti-p38 [Novus Biologicals, #NBP1-97545], anti-EED [abcam, #4469], 
anti-EZH2, anti-phospho-p38, or anti-SUZ12 [Cell Signaling, #5246, #9216, #3737, 
respectively]) overnight at 4°C. Next day, protein–antibody complexes were captured 
with Protein G agarose beads for 2 hours, washed in stringent conditions and eluted in 
laemmli sample buufer. Inputs and IPs were separated as by above described Western 
blot protocol. Immunoprecipitated EED was detected using Clean-Blot™ IP HRP 
(Thermo Scientific, #21230) to avoid interference from denatured IgG.  
 
Proliferation Assays 
Proliferation assays were conducted using the FluoReporter Blue Fluorometric 
dsDNA Quantitation Kit (Molecular Probes, #F-2962) following protocol instructions. 
SUM149, MDA-MB-231 and Primary Tumor breast cancer cells were plated at a density 
of 1000-2000 cells per well in a 96 well plate with at least 8 wells per condition. For the 
next seven days, Hoechst 33258 DNA staining was completed using kit reagents and 







Invasion and motility assays 
In vitro invasion was done using Matrigel Invasion Chambers (BD Biosciences, 
#354480) according to the manufacturer's instructions, in triplicate. Invasive cells 
located on the lower sides of chambers were crystal violet stained, air-dried and 
photographed. They were quantified using ImageJ to count colored pixels, or for 
colorimetric assays, inserts were treated with 10% acetic acid to remove dye and the 
absorbance was measured at 560nm using a spectrophotometer. 
Random motion cell motility assays were completed as previously described [24]. 
Briefly, cells were plated on collagen-coated chambered coverslips at low density 
attaching overnight. Next day, cells were imaged every 10 minutes at 37⁰C for 24 hours 
using the DeltaVision RT Live Cell Imaging System (Applied Precision, GE Healthcare) 
equipped with a UPlanAo 20X/0.7 NA lens at the University of Michigan Microscopy and 
Image analysis Laboratory. DIC images were acquired using SoftWoRx 3.5.1 software, 
and individual cell movements were quantified using MTrackJ /ImageJ software. 
  
Real-time RT-PCR 
Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) 
amplifications were carried out with 1µg of total RNA isolated from the indicated breast 
cells and conditions. Reactions were performed in triplicate using an Applied 
Biosystems StepOnePlus RT-PCR System available in the Michigan MicroArray Core 
with Qiagen primers and SYBR Green Master Mix (Applied Biosystems, #4309155). All 




#PPH00715B-200, MAPK14 (p38α) #PPH00750B-200, MAPK11 (p38β) #PPH01778B-
200, MAPK12 (p38γ) #PPH01779A-200, and MAPK13 (p38δ) #PPH00188B-200. 
 
In vitro methylation 
The in vitro methylation assay was completed as previously described [29]. 
Briefly, 1µg recombinant p38α-GST (BPS Bioscience, #40070) was incubated with 5μl 
methylation buffer (20mM Tris-HCl [pH 7.8], 5mM DTT, 0.5mM EDTA, 10% glycerol) in 
the presence of 10μM H3-S-Adenosylmethionine, with or without the presence of 2µg 
purified PRC2 complex (total protein amount), at 30°C for 1 hr. Samples were then 
separated via SDS-PAGE, the gel was coomassie-stained to visualize proteins, and 
methylation was detected by autoradiograph at 21 days. We thank Yali Dou and Bo 
Zhou for assistance with this assay. 
 
Spontaneous metastasis assay  
Ten-week-old severe combined immunodeficiency mice (Jackson Laboratories) 
were used for examining tumorigenicity as previously reported [20]. Briefly, MDA-MB-
231 cells expressing shEZH2 or scrambled control were orthotopically injected into the 
mammary fat pad at a concentration of 2 × 106 cells in 20 mice (n=10 per group). Tumor 
size was measured twice a week until tumors reached 2 cm3 (tumor volume=(length x 
width2)/2), at which time mice were sacrificed and primary tumor and lung tissues were 
collected. Tissues were formalin-fixed and paraffin-embedded for H&E staining and 
immunohistochemical staining with anti-EZH2 (Cell Signaling, #5246), anti-Cytokeratin-




#RM-9106, 1:2000), or anti-ACTIVE®-p38 MAPK (Promega, #V1211, 1:325); see the 
Immunohistochemistry section for a detailed staining protocol. Image analysis and 
quantification of only metastatic cells to determine the percentage of relative stained 
area was completed using FRIDA (FRamework for Image Dataset Analysis), a custom 
open source image analysis software package for the analysis of RGB color image 
datasets [30]. Additional information can be found at http://bui3.win.ad.jhu.edu/frida/. All 
procedures involving mice were approved by the University Committee on Use and 
Care of Animals at the University of Michigan and conform to their relevant regulatory 
standards. 
 
Human breast tissue microarray 
A high-density tissue microarray (TMA) containing 16 human primary invasive 
breast carcinomas with matched metastases was employed as previously reported [31, 
32]. Immunohistochemistry on formalin-fixed, paraffin-embedded tissue blocks was 
performed using anti-EZH2 (Cell Signaling, #5246, 1:150) and anti-phospho-p38 MAPK 
(Cell Signaling, #9216, 1:3000); see the Immunohistochemistry section for a detailed 
staining protocol. EZH2 and p-p38 expression was evaluated as low or high based on 
intensity of staining and percentage of staining cells, following published literature [33]. 
The complete clinical and pathological information on these tumors is shown in Figure 
1-11. We thank Dr. Ashley Cimino-Mathews and Dr. Pedram Argani at The Johns 
Hopkins Hospital for making the tissue microarray available to our laboratory for staining 






Formalin fixed, paraffin embedded tissue blocks were sectioned at 5u and placed 
on charged slides. Slides were deparaffinized in xylene and rehydrated through graded 
alcohols. Heat Induced Epitope Retrieval (HIER) was performed in the Decloaking 
Chamber (Biocare Medical) with Target Retrieval, pH 6.0 (DakoCytomation). Slides 
were incubated in 3% Hydrogen Peroxide for 5 minutes to quench endogenous 
peroxidases. Primary tumor tissue, mouse tissue and human TMA tissue slides were 
incubated for 1.5 hours at room temperature with previously indicated antibodies. 
Antibodies were detected with either anti-rabbit or anti-mouse Envision+ HRP Labelled 
Polymer (DakoCytomation) for 30 minutes at room temperature. HRP staining was 
visualized with the DAB+ Kit (DakoCytomation). Negative control slides were run. Slides 
were counterstained in hematoxylin, blued in running tap water, dehydrated through 
graded alcohols, cleared in xylene and then mounted with Permount. 
2-4. Results 
EZH2 knockdown induces a mesenchymal-to-epithelial transition and decreases 
the ability of breast cancer cells to move. 
EZH2 overexpressing breast carcinomas have aggressive clinical behavior, high 
frequency of estrogen receptor negative status (ER-) and are associated with a high 
propensity to metastasize [17]. However, direct evidence that EZH2 regulates cancer 
cell phenotype and motility are lacking. To test the hypothesis that EZH2 knockdown 
may reduce the ability of breast cancer cells to move and invade into the surrounding 
tissues, we employed breast cancer cell lines MDA-MB-231 and SUM149, both of which 




comparison to nontumorigenic breast cell lines [20]. We utilized two independent and 
complementary methods to downregulate EZH2 protein levels in breast cancer cells: 
stable expression of a short hairpin RNA interference (shRNA) in a lentiviral vector and 
pharmacologic inhibition using 3-Deazaneplanocin A (DZNeP), a histone 
methyltransferase inhibitor which disrupts PRC2 (Fig. 2-1, A). As we previously reported 
that shRNA knockdown of EZH2 significantly reduced proliferation [20], we performed 
proliferation assays to confirm that DZNeP treatment also induced a decrease in 
proliferation (Fig. 2-1, B).   
EZH2 knockdown through either shRNA or DZNeP treatment was sufficient to 
induce a morphologic and a molecular mesenchymal-to-epithelial transition (MET) of 
SUM149 and MDA-MB-231 cells when compared to scrambled shRNA or untreated 
controls, respectively (Fig. 2-2, A-D). The observed morphologic change was 
associated with a protein expression profile characteristic of MET: increased expression 
of the epithelial markers Cytokeratin-18 and E-cadherin and decreased expression of 
the mesenchymal markers Vimentin and Snail1 (Fig. 2-2, A-B). Knockdown of EZH2 
with shRNA or DZNeP significantly reduced invasion in MDA-MB-231 and SUM149 
cells when compared to corresponding controls (Fig. 2-2, E-F). Extending the relevance 
to human disease, EZH2 knockdown with DZNeP significantly decreased proliferation 
and invasion in primary breast cancer cells derived from a patient diagnosed with a 
triple negative, grade 3, invasive ductal carcinoma (Fig 2-3, A-D).  
We next investigated the role of EZH2 on cell motility, a critical step in 
metastasis. Random cell motion was quantified using live cell imaging with time-lapse 




MDA-MB-231 cells significantly decreased the average cell velocity when compared to 
controls (Fig. 2-4, A-B). Furthermore, rescue of EZH2 expression using a myc-tagged 
EZH2 adenovirus partially reversed the decreased motility induced by EZH2 knockdown 
in MDA-MB-231 cells (Fig. 2-4, C). Collectively, these experiments show that EZH2 
downregulation promotes a MET and reduces the motility and invasiveness of breast 
cancer cells.  
 
EZH2 regulates the levels of phosphorylated p38 protein and signaling pathway.   
p38 has emerged as an important  regulator of cell migration and metastasis in 
breast cancer models [23, 24, 33]. Whether EZH2 influences the levels and function of 
p38 in human breast cancer is unknown. We found that EZH2 downregulation with 
shRNA or DZNeP reduced p-p38 protein and the phosphorylation of downstream 
targets MAPKAPK-2 (MK2) and Heat Shock Protein 27 (HSP27) in breast cancer cell 
lines and primary breast cancer cells when compared to controls (Fig. 2-5, A-B). No 
significant effect on the protein levels of total p38 was observed by EZH2 knockdown. 
Conversely, adenoviral overexpression of myc-tagged EZH2 in nontumorigenic 
MCF10A breast cells and in MCF7 breast cancer cells consistently led to upregulation 
of p-p38 protein levels when compared to controls (Fig. 2-5, C).  
To further define the mechanistic link between EZH2 and p38, we tested whether 
p-p38 regulates the levels of EZH2 and other core components of PRC2. Treatment 
with SB203580 or SB202190, which inhibit the ability of activated p-p38 to 
phosphorylate downstream targets, such as HSP27, had no effect on EZH2, SUZ12, 




indicate that EZH2 levels in breast cancer cells are not affected by the p38 signaling 
pathway.  
We next investigated whether EZH2 regulates a specific p38 isoform by testing 
the effect of EZH2 knockdown on the expression of phosphorylated p38α, p38β, p38γ 
and p38δ. As phospho-specific isoform antibodies are not available, total p-p38 was 
immunoprecipitated from whole cell extracts of MDA-MB-231 and SUM149 cells 
expressing scrambled or EZH2-targeted shRNA followed by Western blot analysis for 
the four isoforms. EZH2 knockdown decreased the phosphorylated levels of all isoforms 
when compared to controls, while total p38 isoform protein levels remained unaffected 
(Fig. 2-6, B). Further supporting a non-transcriptional role for EZH2 in the regulation of 
p-p38, quantitative real-time RT-PCR showed that neither knockdown nor 
overexpression of EZH2 affected the mRNA levels of total p38 or the individual p38 
isoforms when compared to controls (Fig. 2-6, C). Collectively, these results show that 
EZH2 regulates the phosphorylated levels of all p38 isoforms in breast cancer cells and 
suggest either an indirect transcriptional or a post-transcriptional regulatory mechanism.  
 
EZH2 protein binds with phosphorylated p38 protein. 
To further understand the mechanism by which EZH2 regulates p-p38, we tested 
the hypothesis that EZH2 may bind to p-p38 in breast cancer cells. Immunoprecipitation 
and Western blot analyses revealed that endogenous EZH2 protein interacts with p-p38 
in SUM149 and MDA-MB-231 breast cancer cells; and that the binding is reduced by 
EZH2 knockdown, thereby supporting the specificity of the interaction (Fig. 2-7, A-B). 




protein binds to p38/p-p38 protein in association with EED and SUZ12 (Fig. 2-7, B). As 
PRC2 functions in protein methylation, we hypothesized that PRC2 may methylate p38. 
Even though all p-p38 isoforms were affected by EZH2 protein expression, we chose to 
analyze p38α because it is the most abundant and ubiquitously expressed [34].  An in 
vitro methylation assay shows that addition of PRC2 leads to p38α protein methylation 
(Fig. 2-7, C). Collectively, these data demonstrate that EZH2 binds to p-p38 in 
association with PRC2, and show that PRC2 can methylate p38α in vitro, which paves 
the way for future mechanistic investigations.  
 
EZH2 knockdown is sufficient to reduce distant metastasis. 
We previously demonstrated in a xenograft mouse model that stable EZH2 
knockdown in MDA-MB-231 cells decreased the rate of breast tumor growth and the 
volume of tumors and improved survival, but the effect of EZH2 downregulation on the 
development of distant metastases in these mice was not determined [20]. Compared to 
the scrambled shRNA control, EZH2 knockdown reduced the ability of MDA-MB-231 
cells to form spontaneous lung metastasis when injected into the mammary fat pads of 
NOD/SCID mice (Fig. 2-8, A-B). Histological analysis of lung tissues collected when 
primary tumors reached 2 cm3, revealed that 8 of 10 (80%) MDA-MB-231/control mice 
developed metastases compared with 6 of 10 (60%) of MDA-MB-231/shEZH2 mice. 
Although no significant difference was observed in the number of mice developing lung 
metastases between conditions, the metastatic burden as determined by the number of 
lung metastases per mouse was significantly reduced in shEZH2 mice in comparison to 




smaller than controls; the average sizes of the largest lung metastasis per mouse were 
304µm and 737µm from shEZH2 and control mice, respectively. 
Consistent with our functional findings, pathological analyses revealed a change 
in the invasive pattern of the breast cancer cells at the metastatic site. The metastases 
formed by control cells exhibited irregular and infiltrative borders, and encased pre-
existing normal structures such as bronchioles and blood vessels (Fig. 2-8, A). In 
contrast, metastases formed by shEZH2 cells were smaller and circumscribed, with 
round borders and minimal parenchymal infiltration (Fig. 2-8, A). Consistent with the in 
vitro data and the histopathological findings, metastases formed by shEZH2 cells 
exhibited increased Cytokeratin-18 and decreased Snail1 proteins compared to 
metastases formed by the controls, as demonstrated by double immunohistochemical 
analyses (Fig. 2-8, A); this effect was also observed in the primary xenografts (Fig. 2-9, 
A). EZH2 knockdown metastases had significantly reduced cell proliferation as 
measured by Ki67 immunohistochemical staining compared to controls, complementing 
the previous data which showed decreased mitotic activity in the primary breast cancers 
(Fig. 2-9, B). Supporting our in vitro observations and mechanistic studies, shEZH2 lung 
metastases had decreased p-p38 levels when compared to controls (Fig. 2-9, C). 
 
Human breast cancer metastases exhibit high EZH2 and p-p38 protein 
expression. 
The relevance of these novel findings to human breast cancer was validated by 
examining the expression of EZH2 and p-p38 proteins in a unique cohort of primary 




microarrays [31, 32]. The patients in the cohort varied in age from 33 to 58 years old at 
diagnosis, and all had been initially diagnosed with invasive carcinoma. The interval to 
metastasis in the patients ranged from at time of initial diagnosis to seven years.  
Distant metastases were found in lung, brain, ovarian, pancreatic and bowel tissues. 
When present, both proteins predominantly localized to the nuclei of breast cancer cells 
(Fig. 2-10, A-B). EZH2 and p-p38 were scored as exhibiting low or high expression 
according to a previously validated schema [17, 33]. We found that EZH2 was 
significantly upregulated in all metastases when compared to primary carcinomas, and 
that EZH2 and p-p38 were co-expressed in 63% of the metastases (Fig. 2-10, C). The 
complete clinical and pathological information, including individual EZH2 and p-p38 
scoring, on these tumors is shown in Figure 2-11. 
2-5. Discussion 
The data presented here reveal the previously undescribed findings that 
downregulation of EZH2 leads to MET and decreases motility in breast cancer cells. We 
show for the first time that EZH2 knockdown is sufficient to reduce distant metastasis in 
vivo. We uncovered a novel mechanism of EZH2 function by which EZH2 protein binds 
to p-p38 and leads to upregulated expression of p-p38 protein and its signaling pathway 
in breast cancer cells. 
It has become increasingly evident that cancer cell plasticity influences the 
biologic behavior of breast cancer by allowing the conversion between epithelial and 
mesenchymal states [35]. EMT describes the reversible and dynamic process in which 
epithelial cells, characterized as organized and polarized cells closely attached by 




characterized by a lack of polarization and intercellular junctions. The process of 
epithelial cancer cells acquiring attributes of mesenchymal-like cells and being driven 
towards a motile state and metastasis is referred to as oncogenic EMT [35]. One of the 
hallmarks of EMT is the reduction of normal expression of the cell-cell junction protein 
E-cadherin [36]. We and other investigators have reported that EZH2 overexpression 
induces invasion in nontumorigenic breast and prostate cells, and decreases the 
expression of E-cadherin [27]. However, whether EZH2 can influence EMT and motility 
of breast cancer cells has not been previously considered. In this study, we show that 
EZH2 downregulation in breast cancer cell lines is sufficient to reprogram the phenotype 
of the cells from a spindle to an epithelial morphology with upregulation of E-cadherin 
and Cytokeratin-18, and downregulation of the mesenchymal protein Vimentin and the 
EMT transcription factor Snail1. The molecular and morphologic features indicative of 
EMT are tightly associated with the ability of cancer cells to migrate and invade, 
enabling metastasis. We found that EZH2 downregulation decreased invasion and 
motility in breast cancer cell lines. Time-lapse microscopy demonstrated that EZH2 
downregulation decreased average cell velocity compared to controls.  
p38 has been established as a regulator of transitions between epithelial and 
mesenchymal states as well as cancer cell migration [23, 24, 33]. Activated p-p38 
regulates transcription factors responsible for E-cadherin repression including Snail1, 
Slug and Twist inducing a mesenchymal-like phenotype [37-40]. During TGF-β-induced 
EMT, p38 activation increases breast cancer lung metastasis [41]. p38α activity is 
required for the invasive capability of breast, pancreatic, hepatocellular, and head and 




metalloproteinases implicated in extracellular remodeling and degradation [33, 42-50]. 
Also, p38δ has been proposed to regulate the invasion of squamous cell carcinoma, 
while p38γ has been associated with Ras-induced invasion [43, 51]. Recently, down-
regulation of p38γ markedly decreased the cell motility of breast cancer cells in vitro 
[24]. In human cancers, increased expression of p38α has been associated with cancer 
progression and poor prognosis in a number of malignancies, including breast 
carcinoma [43, 44, 52-55]. Despite the important role of p38 in motility, invasion and 
metastasis of human cancer, the mechanisms regulating its activation are still being 
defined. Through a combination of knockdown and overexpression strategies, EZH2 
emerges as a novel regulator of p-p38 protein levels and the levels of its downstream 
signaling proteins in nontumorigenic breast cells and breast cancer cell lines.  
The mechanisms implicated in the oncogenic role of EZH2 need further 
investigation. EZH2 has been considered largely a transcriptional repressor of tumor 
suppressor genes as part of PRC2, but recent evidence supports contextual, activating 
functions of EZH2 [7-13]. Here, we demonstrate that EZH2 regulates p-p38 via a non-
transcriptional mechanism. We found that EZH2 had no effect on the mRNA levels of 
p38 isoforms using quantitative RT-PCR. Unexpectedly, in breast cancer cells, 
endogenous EZH2, EED and SUZ12 proteins bind to p-p38 protein, and that 
downregulation of EZH2 abrogates the binding of EZH2 and p-p38. Our in vitro 
methylation assay results suggest that PRC2 may methylate p-p38, and paves the way 
for future studies. Our data lead to the novel hypothesis that EZH2 in association with 





Our group has previously reported that high EZH2 protein expression is 
associated with the development of metastasis in breast cancer and worse clinical 
outcome [17]. Data presented here show for the first time that EZH2 knockdown 
reduces the number of distant breast cancer metastases in vivo. EZH2 knockdown in 
highly aggressive MDA-MB-231 cells decreased the metastatic burden and reduced the 
invasiveness of breast cancer cells at the metastatic site, as well as the expression of p-
p38. In paired human samples of primary and metastatic carcinomas, EZH2 was 
significantly overexpressed at the metastatic site. Furthermore, co-expression of EZH2 
and p-p38 were detected in 63% of the metastatic carcinomas.  
In conclusion, our results demonstrate a previously unknown mechanism of 
EZH2 function in breast cancer metastasis. We have shown that EZH2 inhibition in 
breast cancer cell lines leads to a phenotypic change from mesenchymal to epithelial, 
with reduced motility, invasion and metastasis. We uncover a previously unknown 
molecular mechanism by which EZH2 binds to p-p38 and regulates the activation of the 
p38 signaling pathway. From a clinical perspective, the role of EZH2 in p38 signaling is 
of particular interest as activation of this pathway can be detectable and targetable in 








Figure 2-1 EZH2 knockdown in breast cancer cell lines can be achieved with 
targeted shRNA or DZNeP treatment and leads to decreased proliferation.  
(A) Immunoblots of SUM149 and MDA-MB-231 breast cancer cells show that 
downregulation of EZH2 protein can be accomplished with either [top] EZH2-targeted 
shRNA [shEZH2] or [bottom] 1µM DZNeP treatment when compared to scrambled 
control shRNA [Scr] or untreated controls, respectively. (B) EZH2 downregulation with 
DZNeP reduces proliferation of SUM149 [top] and MDA-MB-231 [bottom] breast cancer 
cells as measured by Hoechst DNA staining and fluorescence emission at 460nm ± SD 













Figure 2-2 EZH2 knockdown induces a mesenchymal-to-epithelial transition and 
decreases invasion in breast cancer cells.  
(A&B) Immunoblots of SUM149 and MDA-MB-231 breast cancer cells show that 
downregulation of EZH2 protein with either (A) EZH2-targeted shRNA [shEZH2] or (B) 
1µM DZNeP treatment leads to a protein expression profile indicative of epithelial 
differentiation compared to scrambled control shRNA [Scr] or untreated controls, 
respectively. E-cadherin and Cytokeratin-18 [CK-18] represent epithelial marker 
proteins, and Vimentin and Snail1 represent mesenchymal marker proteins. (C&D) 
Representative phase contrast images show that EZH2 knockdown with either (C) 
shEZH2 or (D) DZNeP in SUM149 and MDA-MB-231 cells leads to a morphological 
change from mesenchymal-like to epithelial when compared to corresponding controls 
[200X magnification]. (E&F) EZH2 knockdown with either (E) shEZH2 or (F) DZNeP 
reduces invasion of SUM149 and MDA-MB-231 cells compared to corresponding 
controls using a reconstituted Boyden basement membrane invasion chamber assay. 
Left, representative images of either (E) entire chambers or (F) fields of chambers 
[200X magnification] which have been stained are shown; right, mean invaded area ± 
SD was calculated by either (E) quantifying stained image pixels using ImageJ 
[Student’s t-test, *p<0.0002, **p=0.03] or (F) using colorimetry with absorbance at 
560nm ±SD [Student’s t-test, *p=0.002, **p=0.01]. 
 










Figure 2-3 EZH2 downregulation decreases proliferation and invasion in primary 
patient breast cancer cells.  
(A) Representative photomicrographs of hematoxylin and eosin [H&E] staining and 
EZH2 immunostaining of a patient tumor sample obtained from a primary invasive 
ductal breast carcinoma [Primary Tumor, 400X magnification]. (B) Immunoblots for 
EZH2 in primary cell cultures derived from the tumor sample described in (A) 
demonstrate EZH2 protein downregulation with 1µM DZNeP treatment compared to 
untreated controls. (C) EZH2 downregulation reduces proliferation of primary tumor 
cells as measured by Hoechst DNA staining and fluorescence emission at 460nm ± SD 
[Student’s t-test, *p<0.001]. (D) EZH2 downregulation reduces invasion of primary tumor 
cells. Left, representative fields of invaded and stained Boyden chambers are shown 
[200X magnification]; right, invasion was quantified using colorimetry with absorbance at 

















Figure 2-4 EZH2 knockdown decreases breast cancer cell motility.  
(A & B) Left, representative images displaying MTrackJ individual MDA-MB-231 cell 
tracks, colored dots and connecting lines, from 24 hour time-lapse videos of (A) 
scrambled shRNA control and shEZH2 or (B) untreated and DZNeP treated cells [200X 
magnification]. Each dot represents a 10 minute time span and closely spaced dots 
indicate less movement over the elapsed time versus widely spaced dots. Right, bar 
graphs show that EZH2 KD cells are significantly slower than controls as demonstrated 
by the average cell velocity ± SEM [Student’s t-test, *p<1×10−5, n ≥25 cells per 
condition]. (C) Transient rescue of EZH2 expression in MDA-MB-231 EZH2 KD cells 
using a myc-tagged EZH2-encoding adenovirus reverses the decreased motility of 
EZH2 KD cells. Representative images displaying cell tracks of shEZH2 cells infected 
with either control or EZH2 adenovirus [200X magnification]. The bar graph shows that 
shEZH2 cells with EZH2 adenoviral rescue are significantly faster than control 
adenoviral infected cells as demonstrated by the average cell velocity ± SEM [Student’s 






Figure 2-5 EZH2 regulates the activation of the p38 MAPK signaling pathway.  
(A) Immunoblots of SUM149 and MDA-MB-231 breast cancer cells show 
downregulation of EZH2 protein with EZH2-targeted shRNA [shEZH2] have decreased 
levels of phosphorylated p38 [p-p38] and its activity as demonstrated by the 
phosphorylation of downstream signaling targets, MK2 and HSP27 when compared to 
scrambled shRNA control cells [Scr]. (B) Immunoblots of SUM149, MDA-MB-231 and 
Primary Tumor breast cancer cells show that EZH2 knockdown with DZNeP treatment 
decreases the levels of p-p38 and its downstream phosphorylating activity. (C) 
Immunoblots of MCF7 breast cancer cells and nontumorigenic MCF10A breast 
epithelial cells show that p-p38 levels are increased with adenoviral myc-tagged EZH2 













Figure 2-6 EZH2 regulates the activation of total and isoform specific protein 
levels of p38. 
(A) Immunoblots show that inhibition of p-p38 phosphorylating activity in MDA-MB-231 
cells with SB202190 or SB203580 at two different concentrations for 48 hours does not 
affect the levels of EZH2, SUZ12, EED or H3K27me3. (B) Activated, phosphorylated 
levels of all four p38 isoforms, but not total isoform protein levels, are decreased in 
SUM149 [left] and MDA-MB-231 [right] shEZH2 cells when compared to scrambled 
shRNA control cells [Scr]. Total p-p38 was immunoprecipitated from whole cell extracts 
followed by Western blot analysis for the four individual isoforms. (C) Quantitative real-
time RT-PCR reveals that EZH2 knockdown in SUM149 and MDA-MB-231 breast 
cancer cells or transient adenoviral overexpression in nontumorigenic MCF10A breast 
cells has no significant effect on the mRNA levels of total p38 or of any of the four p38 
isoforms when compared to controls. mRNA expression is shown relative to GAPDH 
mRNA levels ± SD. 
 
(Figure on previous page). 
 
Figure 2-7 EZH2, along with the PRC2 complex, binds to phosphorylated p38 and 
can methylate p38α in vitro.  
(A) Co-immunoprecipitations from whole cell extracts of SUM149 shEZH2 and 
scrambled shRNA control cells show that endogenous EZH2 immunoprecipitates with 
endogenous p-p38. Extracts were immunoprecipitated with EZH2, p-p38 or control IgG 
and bound proteins were revealed by Western blot via antibodies against EZH2 and p-
p38. (B) Co-immunoprecipitations from whole cell extracts of SUM149 cells show that 
EZH2 binds p38/p-p38 in association with PRC2 members SUZ12 and EED. Extracts 
were immunoprecipitated with EZH2, p38, p-p38, EED, SUZ12 or control IgG and 
bound proteins were revealed by Western blot via antibodies against EZH2, p38, p-p38, 
EED and SUZ12. (C) In vitro methylation assay reveals that the addition of the PRC2 
complex leads to the methylation of GST-p38α.  
 























Figure 2-8 EZH2 knockdown in MDA-MB-231 cells is sufficient to reduce distant 
metastasis.  
(A) Representative photomicrographs of mouse lung metastases of MDA-MB-231 
scrambled shRNA control or EZH2-targeted shRNA [shEZH2] cells. EZH2 knockdown 
changed the tumor morphology from poorly circumscribed and highly invasive areas 
towards small, circumscribed foci. The asterisk shows a vessel encased by metastatic 
carcinoma. The arrows indicate metastases formed by MDA-MB-231 shEZH2 cells. 
Double immunostain with anti-Cytokeratin-18 [CK-18, red] and anti-Snail1 [brown] 
antibodies show that shEZH2 metastases exhibit upregulation of epithelial marker CK-
18 and decreased expression of mesenchymal marker Snail1 in the nuclei of cancer 
cells compared to controls [H&E: 200X magnification; H&E-Inset: 400X magnification; 
CK-18/Snail1, EZH2: 600X magnification]. (B) EZH2 knockdown significantly reduced 
the number of lung metastases per mouse. Whiskers indicate the minimum and 
maximum number of lung metastases per mouse for each condition [Student’s t-test, 
*p<0.05].  
(Figure on previous page) 
Figure 2-9 Primary xenografts exhibit MET and lung metastases have significantly 
reduced expression of Ki67 and p-p38 with EZH2 knockdown in MDA-MB-231 
cells.  
(A) Representative photomicrographs of MDA-MB-231 scrambled control and shEZH2 
primary xenografts with immunostaining for the epithelial marker CK-18 [red] and the 
mesenchymal marker Snail1 [brown, 400X magnification]. Arrow indicates the invasive 
edge of the tumor, on right, into the surrounding stroma, on left. (B) Left, representative 
photomicrographs of MDA-MB-231 control and shEZH2 lung metastases with 
immunostaining for the proliferative marker Ki67 [400X magnification]. Dotted line 
indicates boundaries of the shEZH2 lung metastasis. Right, bar graph shows Ki67 
protein expression ± SEM in shEZH2 and control lung metastases quantified using 
FRIDA software [Student’s t-test, *p=0.03]. (C) Left, photomicrographs of lung 
metastases of MDA-MB-231 control and shEZH2 cells exhibit decreased p-p38 protein 
[600X magnification]. Right, bar graph shows p-p38 protein expression ± SEM in 
shEZH2 and control lung metastases quantified using FRIDA software [Student’s t-test, 
*p=0.01]. 
 











Figure 2-10 EZH2 and p-p38 are significantly upregulated in human breast cancer 
metastases when compared to matched primary tumors from the same patient.  
(A) Representative images of matched primary human breast carcinomas and 
metastases (n=16 patients) immunostained for EZH2 [100X magnification, Inset: 400X 
magnification]. EZH2 is upregulated in the metastasis compared to the primary tumor. 
(B) Representative images of two metastases showing concordant high EZH2 and p-
p38 expression [600X magnification] (C) The table shows the distribution of EZH2 and 
p-p38 protein expression in the 16 primary breast carcinomas and matched metastases; 





Figure 2-11 Table of the complete clinical and pathological information, including EZH2 and p-p38 protein 
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EZH2 expands the stem cell population in benign and tumorigenic breast cells 
through regulation of Notch1 signaling 
The following chapter represents a “manuscript in progress” and will be submitted for 
publication under the above title by Maria E. Gonzalez, Heather M. Moore, Xin Li, Kathy 
A. Toy, Kelley Kidwell, and Celina G. Kleer. 
3-1. Abstract 
Breast cancer is the second leading cause of cancer-related deaths in women, 
but the details of how it begins remain elusive. Increasing evidence supports the 
association of aggressive breast carcinomas with heightened expression of the 
Polycomb group transcriptional repressor EZH2 and increased numbers of tumor-
initiating cells, often termed cancer stem cells (CSCs). However, mechanistic links 
between EZH2 and CSCs have remained unclear, and direct demonstration that EZH2 
induces breast cancer development is lacking. We demonstrate in vitro that levels of 
EZH2 expression strongly correlate with stem cell numbers in nontumorigenic and 
tumorigenic breast cells. EZH2 overexpression in nontumorigenic breast cells leads to 
an increase in stem cells, whereas EZH2 downregulation in breast cancer cells leads to 
a decrease in CSCs. Mechanistically, we uncover a novel role of EZH2 in activating, 




binding was found to be independent of its catalytic methyltransferase activity and the 
PRC2 complex, but corresponded instead to transcriptional activation marks. Inhibition 
of Notch1 activity prevented the EZH2-induced expansion of stem cell populations. We 
demonstrate in vivo that EZH2 overexpression promotes earlier breast cancer initiation 
and correlates with Notch1 expression in a transgenic breast cancer mouse model. In 
human clinical breast cancer tissues, we found that EZH2 and Notch1 were 
coexpressed in 44% of invasive breast carcinomas, while the expression of both 
proteins were absent in 35% of cases. In addition, EZH2, Notch1 and CD44+/CD24-/low 
were coexpressed in 26% of tumor tissues, consistent with the in vitro functional results. 
These findings reveal a novel functional and mechanistic link between EZH2 
expression, Notch1 signaling, and stem cell levels, and provide evidence that EZH2 
enhances breast cancer initiation. 
3-2. Introduction 
It is thought that breast cancer arises through a continuum from epithelial cells in 
the terminal-ductal-lobular-unit, the functional unit of the breast. Normal cells may 
undergo hyperplasia and develop epithelial atypia, which may progress to ductal 
carcinoma in situ, and eventually to invasive carcinoma. Invasive carcinoma is 
characterized by abnormal proliferation and differentiation, and by the ability to invade 
normal tissues. The presence of cells lacking structural or functional differentiation, 
known as anaplasia, is considered a hallmark of cancer. Thus, it is not surprising that 
dysregulation of genes which govern cell type identify may lead to malignant 




maintaining cellular memory by transcriptionally repressing target genes involved in a 
wide array of cellular processes including differentiation, proliferation and stem cell 
maintenance [5-9]. Enhancer of zeste homolog 2 (EZH2) is the catalytic core member of 
the Polycomb Repressive Complex 2 (PRC2) where its most described function is in 
trimethylation of histone 3 lysine 27 (H3K27me3) leading to transcriptional repression 
[10]. EZH2, as a regulator of a number of critical cellular pathways, has been found to 
be upregulated in multiple malignancies of hematopoietic and solid organ origin, where 
its oncogenic activity is thought to be primarily mediated by silencing tumor suppressor 
genes [7-9, 11-13]. However, it has been recently demonstrated in several studies that 
EZH2 may exert transcriptional activating functions in context-dependent manners 
providing a contrasting role for EZH2 in cancer development [14-20].  
EZH2 is overexpressed in clinically aggressive breast carcinomas where it 
independently predicts survival [3]. In benign breast tissues, elevated levels of EZH2 
protein signal future development of breast cancer up to 12 years prior to diagnosis 
indicating that EZH2 upregulation precedes morphological changes of atypia or 
carcinoma [21, 22]. Recently, EZH2 has been shown to play a role in the self-renewal of 
cancer stem cells (CSCs) [23]. However, direct demonstration that EZH2 promotes 
breast cancer initiation is lacking and the responsible mechanisms remain to be 
elucidated. 
The details of how human breast cancer initiates remain unknown. Studies have 
implicated CSCs in having enhanced tumor initiating capacity when compared to non-
stem cells [24-26]. Breast CSCs are defined as a subpopulation of cells having an 




heterogeneity of the primary tumor when transplanted into mice [27]. CSCs can be 
successfully isolated from primary tumor tissue and cultured cell lines. In human breast 
cancer, CSCs are enriched within cell subpopulations with a CD44+/CD24-/low surface 
marker profile and by positive activity of the detoxifying enzyme aldehyde 
dehydrogenase-1 (ALDH1+) [24, 25, 28-32]. Substantive data exist on the signaling 
dynamics and regulatory pathways that control breast CSCs, which include the Notch, 
Hedgehog, Wnt, PI3K, NF-κB, and JAK/STAT pathways [33-35]. In breast cancer, these 
pathways are dynamically regulated rather than activated via mutation [36]. However, 
the molecular mechanisms involved in the maintenance of the CSC pool and in breast 
cancer initiation remain poorly understood.  
 In this study, we demonstrate that EZH2 protein levels correlate strongly with the 
numbers of stem cells in nontumorigenic and malignant breast cells. The 
overexpression of EZH2 observed in breast cancer cell lines translates to an increase in 
stem cells, which can be reduced with EZH2 knockdown. We discover Notch1 
expression, at both the mRNA and protein levels, to be regulated by the levels of EZH2 
expression. Specifically, EZH2 is found to activate transcription of the Notch1 promoter 
and control downstream signaling by interacting with the Notch1 promoter through a 
mechanism independent of H3K27 trimethylation. Notch1 inhibition decreases the 
expansion of stem cells facilitated by EZH2 overexpression. We further show that EZH2 
overexpression confers a distinct tumor initiation advantage to breast CSCs in vivo. In 
analysis of human breast cancers, we found a significant association between EZH2, 
Notch1 and CD44+/CD24-/low protein expression. Together, these findings identify a 




activity, and establish the first evidence that transgenic EZH2 overexpression 
accelerates breast cancer initiation in vivo.  
3-3. Materials and Methods 
Cell culture 
The breast cancer cell line MDA-MB-231 and the immortalized human mammary 
epithelial cell line MCF10A were obtained from the American Type Culture Collection 
and grown under recommended conditions. The SUM149 breast cancer cell line was 
obtained from the S. Ethier laboratory (Karmanos Cancer Institute, Detroit, MI) and 
cultured as previously reported [37]. Human mammary epithelial cells were purchased 
from ScienCell Research Laboratories (#7610) and maintained following the provider’s 
instructions. These cells were delivered frozen after being isolated from normal human 
breast tissue and being cryopreserved at first passage.  
A fresh breast tumor tissue sample was obtained through the Tissue 
Procurement Service at the University of Michigan (IRB#2002-227). The donated 
sample was immediately processed in the laboratory. A portion was formalin fixed and 
paraffin embedded for staining with hematoxylin and eosin (H&E) and 
immunohistochemical staining with anti-EZH2 (Cell Signaling, #5246, 1:150); see the 
Immunohistochemistry section for a detailed staining protocol. Another portion was 
processed to a single cell suspension as previously described [38]. Briefly, the tumor 
specimen was manually minced and then dissociated in a collagenase-hyaluronidase 
solution (StemCell Technologies, #07912). Next, red blood cells were lysed with RBC 




Trypsin-EDTA (GIBCO, #25200-056), then DNase1 (StemCell Technologies, #07900) 
and finally filtered through a 40µm cell strainer. Cells were then cultured in Mammary 
Epithelial Cell Medium (ScienCell, #7611) completed with Mammary Epithelial Cell 
Growth Supplement and penicillin-streptomycin (ScienCell, #7652 and #0503).  
 
Vectors/viral infections and inhibitors 
 EZH2 knockdown using stable short-hairpin interfering RNA in lentivirus was 
completed as previously reported [39]. For targeting EZH2 (NM_152998 NCBI), the 
shRNA oligo ID# V2LHS_17507 was used and corresponded to #RHS4430-99139126 
from Open Biosystems; this oligo was cloned into a pLKO.1-Puro vector and packaged 
into lentiviral particles at the University of Michigan Vector Core. A lentivirus containing 
a plasmid encoding a scrambled shRNA oligo was used for control. Cells were 
transduced and selected for antibiotic resistance with puromycin (Sigma-Aldrich, 
#P9620). Conditional overexpression of EZH2 in MCF10A cells (pLVX-EZH2) was 
achieved through a doxycycline-inducible system previously developed and reported in 
our laboratory [40]. Doxycycline treatments were done for 24 hours at a final 
concentration of 1µg/mL (Clontech, #631311). Transient EZH2 overexpression was also 
achieved through infection with myc-tagged pCMV encoding either wild type or specific 
deletion mutants of EZH2 for 48 hours, as previously reported [3, 41]. 
A pGreenFire lentiviral vector containing a GFP reporter gene driven by four 
transcriptional response elements of the Notch1 gene promoter 
(GTGGGAACGGCATTGTAGCG) was purchased from System Bioscience (#TR020PA-




completed by treating cells with γ-secretase inhibitor (GSI) (Calbiochem, #565750) for 
three days at final 17nM concentration in regular cell culture, and for seven days at a 
final 1.7nM concentration in mammosphere assays.  
 
Western blot analyses 
 Western blot analyses were carried out with 100µg of whole cell extract derived 
as previously reported [40]. Membranes were blocked and incubated with primary 
antibodies in 4% milk (Sigma-Aldrich, #A3059) in TBS-T (Bio-Rad, #161-0372, with 
0.05% Tween20) at 4°C overnight. Mouse monoclonals β-Actin-HRP (Santa Cruz, 
#47778), anti-GAPDH (abcam, #ab9484), anti-α-Tubulin (Sigma-Aldrich, #T9026) and 
rabbit polyclonal anti-Lamin B1 (abcam, #ab16048) were used to confirm equal loading. 
Primary antibodies from Cell Signaling included rabbit monoclonals anti-EZH2 (#5246), 
anti-CCND1 (#2978), anti-phospho-STAT3 (#9145), rabbit polyclonal anti-STAT3 
(#9132), and mouse monoclonal anti-Myc-Tag (#2276). The mouse monoclonals anti-
Notch1 from Santa Cruz (#SC-32745) and anti-Active-β-Catenin from Fisher (#05-665) 
and the rabbit polyclonal anti-Hes1 from abcam (#AB71559) were used.  
 
Mammosphere assays 
 Single cell dissociation for mammosphere formation assays was performed 
following established protocols with SUM149 and MCF10A cells plated at density of 
1x104 cells/mL [25]. Mammospheres were cultured in MammoCult Human Basal 
Medium with added Proliferation Supplement (StemCell Technologies, #05621 & 




end of seven days, for both primary and secondary generations, mammosphere sizes 
and numbers were determined using a Leica inverted microscope. Size was measured 
as the widest diameter with the scale bar.  
 
Signaling microarrays 
 Pathway focused PCR arrays from SABiosciences were used to identify the gene 
expression profiles in the ALDH1+ sorted, SUM149 scrambled and EZH2-targeted 
shRNA cells. The Notch Signaling Pathway PCR array (#PAHS-059Z) and the Stem 
Cell PCR array (#PAHS-0405Z) were performed in triplicate for each condition.  
 
Real-time RT-PCR and ChIP assays 
 Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) 
amplifications were carried out with 1µg of total RNA isolated from the indicated breast 
cells and conditions. Reactions were performed in triplicate using an Applied 
Biosystems StepOnePlus RT-PCR System available in the Michigan MicroArray Core 
with Qiagen primers and SYBR Green Master Mix (Applied Biosystems, #4309155). All 
primers were purchased from Applied Biosystems: Actin (#Hs99999903_m1), GAPDH 
(#Hs99999905_m1), EZH2 (#Hs00544830_m1), and Notch1 (#Hs01062011_m1). 
The ChIP-IT Express Enzymatic kit (Active Motif, #53009) was used following the 
manufacturer’s instructions to perform ChIP assays. Antibodies were used at the 
manufacturer’s recommended dilutions and included anti-EZH2, anti-Histone 
H3K27me2me3, anti-SUZ12, anti-H3K4me2 (Active Motif, #39875, #39535, #39877 & 




promoter primers were purchased from SABiosciences: (Notch1) #GPH1027067(-)01A, 
#GPH1027067(-)02A, #GPH1027067(-)03A, #GPH1027067(-)04A, #GPH1027067(-
)05A and (GAPDH ) #GPH110001C(+)01A. The MYT1 promoter primers used as a 
positive control for EZH2 binding were made as previously reported [42]. ChIP real-time 
PCR was performed in triplicate with isolated DNA as described above.  
 
Flow cytometry 
Aldefluor assay was used for detection of the stem cell population using the 
ALDEFLUOR kit (StemCell Technologies, #01700) following the manufacturer’s 
instructions. Stem cell populations were also measured by labeling 1x106 cells with anti-
CD44 conjugated to APC and anti-CD24 conjugated to PE (BD Biosciences, #559942 & 
#555428) at the manufacturer’s recommended dilutions. For Notch1 promoter reporter 
assays, 1x106 cells transduced with the Notch1 reporter lentivirus (described above), 
were subjected to flow cytometry to determine the percentage of GFP+ cells. All flow 
cytometry analyses were completed using the University of Michigan Flow Cytometry 
Core in triplicate.  
 
Animal studies 
All procedures were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the Institutional Animal Care and 
Use Committee at the University of Michigan. For tumorigenicity experiments, ten-week-
old severe combined immunodeficiency mice (Jackson Laboratories) were used. 




ALDH1- groups, were orthotopically injected into the mammary fat pad at a 
concentration of 1x104 cells in 40 mice (n=10 per group). Tumor size was measured 
twice weekly until tumors reached 2 cm3 (tumor volume=(length x width2)/2), at which 
time mice were sacrificed. To generate EZH2+/neu and EZH2wt/neu transgenic mice, 
female MMTV-neu mice (Jackson Laboratories, #FVB/N-Tg(MMTVneu)202Mul/J) were 
bred with male heterozygous EZH2 transgenic mice using synchronized breeding 
methods [43]. Mammary glands were excised at 8 weeks, 16 weeks and when tumors 
reached 2cm3. Mammary gland whole mounts were prepared by mounting the 
abdominal mammary fat pads on glass slides and processed following established 
protocols [43, 44]. In brief, glands were excised, dehydrated, stained with alum carmine, 
stored in methyl salicylate and mounted with Permount. Mammary gland tissue samples 
for histological analysis were fixed overnight in 10% neutral buffered formalin (Sigma-
Aldrich, #HT501128), processed through graded alcohols, cleared in xylene and 
embedded in paraffin. Tissues were sectioned at 5u and placed on charged slides. 
Slides were H&E stained and immunohistochemically stained with anti-EZH2 (BD 
Biosciences, #612667, 1:250) and anti-Notch1/N-Terminus (Fisher, #07-1232, 1:800); 
see Immunohistochemistry section for a detailed staining protocol.  
 
Human breast tissue microarrays 
High-density tissue microarrays (TMA) containing human primary invasive breast 
carcinomas were employed. Formalin-fixed, paraffin-embedded tissue blocks underwent 
H&E staining and immunohistochemical staining with anti-EZH2 (BD Biosciences, 




#ab51037, 1:400) and anti-Notch1/ N-Terminus (Fisher, #07-1232, 1:800); see the 
Immunohistochemistry section for a detailed staining protocol. Expression for all stained 
proteins was evaluated as low or high based on intensity of staining and percentage of 
staining cells, following published literature [39, 45].  
 
Immunohistochemistry  
Formalin fixed, paraffin embedded tissue blocks were sectioned at 5u and placed 
on charged slides. Slides were deparaffinized in xylene and rehydrated through graded 
alcohols. Heat Induced Epitope Retrieval (HIER) was performed in the Decloaking 
Chamber (Biocare Medical) with Target Retrieval, pH 6.0 (DakoCytomation). Slides 
were incubated in 3% Hydrogen Peroxide for 5 minutes to quench endogenous 
peroxidases. Primary tumor tissue, mouse tissue and human TMA tissue slides were 
incubated for 1.5 hours at room temperature with previously indicated antibodies. 
Antibodies were detected with either anti-rabbit or anti-mouse Envision+ HRP Labelled 
Polymer (DakoCytomation) for 30 minutes at room temperature. HRP staining was 
visualized with the DAB+ Kit (DakoCytomation). Negative control slides were run. Slides 
were counterstained in hematoxylin, blued in running tap water, dehydrated through 
graded alcohols, cleared in xylene and then mounted with Permount.  
3-4. Results 
 
EZH2 levels regulate stem cell numbers in breast cancer cells.  
To examine the effect of EZH2 on the stem cell populations of breast cancer 
cells, we utilized the established breast cancer cell lines SUM149 and MDA-MB-231, 




lines [39]. Downregulation of EZH2 protein was achieved through the stable expression 
of a lentiviral-mediated short hairpin RNA interference (shRNA), whereas re-expression 
of EZH2 protein in knockdown cells was accomplished through transient infection with a 
wild type, EZH2-encoding, myc-tagged adenovirus (Fig. 3-1, A). A sphere-forming 
assay based on the unique property of stem cells to survive in non-adherent, serum-
free, tissue culture conditions was initially used to quantify stem cell activity and self-
renewal [25]. EZH2 knockdown in SUM149 cells significantly reduced the number and 
size of mammospheres in primary and secondary generations when compared to 
scrambled shRNA controls (Fig. 3-1, B). The decrease in mammosphere numbers and 
size was subsequently rescued with re-expression of adenoviral EZH2, but not in 
knockdown cells infected with control adenovirus (Fig. 3-1, B).  
In addition to mammosphere assays, we utilized the positive activity of ALDH1 
(ALDH1+) and the cell surface markers CD44+/CD24-/low to test for CSC subpopulations. 
Intriguingly, in parental SUM149 cells, EZH2 mRNA expression was found to be higher 
in the sorted ALDH1+ population versus the ALDH- population, signifying that EZH2 is 
preferentially expressed at higher rates in CSCs versus non-CSCs (Fig. 3-1, C). In 
support of the mammosphere results, EZH2 knockdown in SUM149 and MDA-MB-231 
breast cancer cells led to a significant decrease in the ALDH1+ and CD44+/CD24- 
populations (Fig. 3-1, D-E & 3-2, A-C). To confirm and extend these observations to 
human breast cancer, we isolated primary cells from an, invasive human breast 
carcinoma exhibiting high endogenous EZH2 protein levels (Fig. 3-2, D). EZH2 
knockdown in primary tumor cells using shEZH2 decreased the CD44+/CD24- 




stem cell pool in breast cancer cells, that EZH2 expression is higher in CSCs versus 
non-CSCs, and that the proliferation of CSCs, as measured by mammopshere size, is 
reduced by EZH2 downregulation.  
We next examined the biological consequences of decreased CSC populations 
due to EZH2 knockdown in vivo. SUM149 ALDH1+ and ALDH1- cell populations 
transduced with either scrambled control or EZH2-targeted shRNA (shEZH2) were 
isolated using the Aldefuor assay. Immediately following sorting, 1x104 cells were 
injected into the cleared mammary fat pads of female NOD/SCID mice, with 10 mice per 
condition, and mice were monitored for tumor growth. In mice injected with ALDH1+ 
cells, EZH2 knockdown markedly decreased the time to tumor development and the 
growth rate of the breast tumors (Fig. 3-3, A-B). Furthermore, the tumors formed from 
ALDH1- cells significantly differed in time to tumor development and tumor volume from 
those formed by control ALDH1+ cells as the time to tumor development and tumor 
volumes from these two groups resembled those of the ALDH+ shEZH2 tumors (Fig. 3-
3, A-B). 
 
EZH2 knockdown reduces Notch1 levels and signaling in breast cancer. 
In order to identify signaling pathways that might mediate the effect of EZH2 on 
breast CSCs numbers, we employed a real time RT-PCR microarray that profiles the 
expression of key genes involved in stem cell signaling. The array was completed in 
triplicate using mRNA prepared from sorted ALDH1+ populations of SUM149 cells 
expressing either scrambled or EZH2-targeted shRNA. Notch1 gene expression was 




when compared to scrambled control cells (Fig. 3-4, A). Of the four Notch receptors, 
EZH2 downregulation primarily reduced Notch1 expression and led to dysregulation of 
downstream signaling components as determined by an additional RT-PCR microarray 
profiling Notch signaling genes (Fig. 3-4, B). Supporting our data, the hitherto unknown 
correlation between EZH2 and Notch1 expression was also observed through 
examination of publicly available cDNA cancer microarray datasets on Oncomine. 
Correlation coefficients above 0.6 for EZH2 and Notch1 expression were obtained 
independently in four invasive breast carcinoma tissue datasets and two breast cancer 
cell lines datasets (Fig. 3-5).  
 The effect of EZH2 knockdown on Notch1 gene expression was consistently 
translated to decreased protein levels of NICD, the activated and intracellular form of 
Notch1, with EZH2 knockdown in SUM149 and MDA-MB-231 breast cancer cell lines 
and in primary patient breast cancer cells (Fig. 3-4, C-D). Consistent with the mRNA 
data, the Notch1 downstream signaling targets Cyclin D1 and β-catenin were reduced at 
the protein level with EZH2 downregulation in SUM149 and MDA-MB-231 cells (Fig. 3-
4, C). Likewise, the downstream targets Hes1 and phosphorylated-STAT3 were 
reduced in primary patient tumor cells with knockdown of EZH2 (Fig. 3-4, D). To 
determine the specificity of EZH2 in the regulation of Notch1 in breast cancer, EZH2 
expression was transiently rescued in SUM149 and MDA-MB-231 shEZH2 cells using 
the EZH2-encoding adenovirus. Indeed, NICD protein expression was effectively 
rescued by the ectopic re-expression of wild type EZH2 in these cell lines (Fig. 3-4, E). 
In all, these data provide evidence that EZH2 depletion reduces the levels and the 




Notch1 signaling regulates EZH2-dependent stem cell expansion.  
It has been shown that Notch1 inhibition reduces breast CSCs, but whether 
Notch1 is required for the effect of EZH2 overexpression in stem cell expansion has not 
been addressed [46-48]. In order to test this hypothesis, we utilized a conditional pLVX-
TetOn system for ectopic EZH2 overexpression (pLVX-EZH2) in the nontumorigenic 
MCF10A breast epithelial cell line. Addition of doxycycline to control pLVX cells showed 
no change in EZH2 mRNA levels, however, a marked upregulation of EZH2 and Notch1 
mRNA levels, principally in the ALDH1+ population, was observed with doxycycline 
addition to pLVX-EZH2 cells (Fig. 3-6, A-B). At the protein level, a concomitant increase 
in EZH2 and NICD expression was seen in doxycycline treated pLVX-EZH2 cells when 
compared to untreated pLVX-EZH2 cells (Fig. 3-6, C). Complementing the previous 
assays conducted in SUM149 breast cancer cells, a significant increase in the number 
and size of primary and secondary mammospheres and in the ALDH1+ and 
CD44+/CD24- populations was induced by doxycycline treatment in pLVX-EZH2 cells, 
but not in control pLVX cells (Fig. 3-6, D-E & Fig. 3-7, A-B). In contrast, when 
doxycycline treated pLVX-EZH2 cells are treated with the γ-secretase inhibitor (GSI), 
preventing the release of NICD from the membrane and blocking Notch1 activity, the 
numbers of mammospheres, ALDH1+ and CD44+/CD24- cells are significantly reduced 
back to pLVX-EZH2 untreated levels (Fig. 3-6, C-E & Fig. 3-7, A-B) [49]. These results 
suggest that Notch1 signaling is required for the increased numbers in stem cell 







EZH2 regulates the Notch1 promoter.   
 As ectopic EZH2 overexpression led to an increase in Notch1 mRNA levels (Fig. 
3-6, B), we hypothesized that EZH2 may regulate Notch1 expression and function 
through interaction with the Notch1 promoter. To test this hypothesis, we investigated 
the effect of conditional EZH2 overexpression in pLVX-EZH2 MCF10A cells in a 
transcription activation reporter assay. A pGreenFire lentiviral vector containing a GFP 
reporter gene driven by four transcriptional response elements of the Notch1 gene 
promoter was utilized. We found that doxycycline treatment of pLVX-EZH2 cells 
revealed an increase in Notch1 transcriptional activity compared to controls, as 
measured by the percentage of GFP-expressing cells (Fig. 3-8, A).  
In order to determine which domains of EZH2 are necessary in the regulation of 
Notch1 transcriptional activity, we generated several myc-tagged EZH2 deletion 
mutants in an adenoviral vector (Fig. 3-8, B). Mutants included deletions of the amino-
terminal HI and HII homology domains, the carboxy-terminal SET domain which is 
necessary for methyltransferase activity, and the nuclear localization signal (NLS). The 
expression of the mutants, compared to wild-type EZH2 adenovirus, in parental 
MCF10A cells was confirmed via Western blot (Fig. 3-8, B). Interestingly, the increase in 
NICD protein levels mediated by ectopic wild type EZH2 expression was not observed 
with expression of any of the deletion mutants (Fig. 3-8, B). Additionally, all of the 
deletion mutants inhibited the Notch1 transcriptional activity previously observed with 
wild type EZH2 upregulation (Fig. 3-8, C). While wild type EZH2 overexpression in 
parental MCF10A cells increased mammosphere numbers and sizes, we found that 




increase (Fig. 3-8, D). These findings signify that EZH2-mediated stem cell expansion 
and Notch1 upregulation require the intact nuclear EZH2 protein. 
 
EZH2 binds to the proximal Notch1 promoter to activate Notch1 transcription.  
EZH2 has been characterized as a transcriptional repressor but there is recent 
evidence suggesting it can contextually activate gene transcription [14-17]. We 
hypothesized that the ability of EZH2 to increase Notch1 expression may be linked 
directly to its ability to bind to the Notch1 promoter. To test this hypothesis, we 
performed chromatin immunoprecipitation (ChIP) assays on primary, nontumorigenic 
breast epithelial cells transduced with adenoviral vectors containing wild-type EZH2 or 
EZH2 mutants, ΔSET and ΔHII. These mutants were selected because the SET domain 
is required for the histone methylating function of EZH2 and the HII domain has been 
reported to promote gene activation [4, 6, 7, 13, 14, 18-20]. Walking primers 
encompassing the Notch1 promoter regions from -532 to -4510 base pairs of the 
transcription start site were used (Fig. 3-9, A). Primers flanking the GAPDH promoter 
region were used as a negative control; and primers flanking the MYT1 promoter region, 
a known direct transcriptional repression target of EZH2 through trimethylation of 
histone 3 lysine 27 (H3K27me3), were used as a positive control [50, 51]. Upon wild-
type EZH2 overexpression in nontumorigenic primary breast cells we observed a 
significant increase in EZH2 binding at the -1.2 kb Notch1 site, which was blocked by 
expression of the ΔHII mutant (Fig. 3-9, B). EZH2 binding to the Notch1 promoter was 
not associated with H3K27me3 or SUZ12 binding, but coincided with increased 




marks (Fig. 3-9, B). These intriguing results strongly suggest that EZH2 binds to the 
Notch1 promoter independent of the Polycomb Repressive Complex 2 (PRC2) and of its 
repressive trimethylating activities, and may instead be leading to transcriptional 
activation. These results further demonstrate that the amino-terminal HII domain is 
indispensible for the binding. 
We next investigated whether the binding of EZH2 protein to the Notch1 
promoter occurs in breast cancer cells with high endogenous levels of EZH2. Indeed, 
ChIP assays demonstrated enrichment for endogenous EZH2 at the Notch1 promoter in 
MDA-MB-231 cells and in primary patient breast cancer cells (Fig. 3-9, C-D). 
Consistently, EZH2 binding was associated with enhanced H3K4 methylation and 
occurred independent of SUZ12 and H3K27me3 binding. Stable knockdown of EZH2 in 
MDA-MB-231 cells decreased the binding of EZH2 to the Notch1 promoter, validating 
the specificity of the interaction (Fig. 3-9, C). Taken together, these data identify a 
previously undescribed function of EZH2 that involves binding to the Notch1 promoter to 
activate transcription.  
 
Transgenic EZH2 overexpression upregulates Notch1 and accelerates tumor 
initiation in MMTV-neu mice.  
We were interested to determine whether the observed in vitro effects of EZH2 
on breast stem cells translated to an in vivo model. Towards this end, we genetically 
overexpressed EZH2 in the MMTV-neu transgenic breast cancer mouse model by 
crossing MMTV-neu mice with the MMTV-EZH2 transgenic mice developed previously 
in our laboratory rendering EZH2+/neu and control EZH2wt/neu mice [43, 52]. Virgin 




branches compared to the EZH2wt/neu mice as early as 8 weeks of age, which 
persisted at 16 weeks of age (Fig. 3-10, A). Providing in vivo validation to our 
mechanistic studies, EZH2+/neu mice developed mammary glands with atypical 
intraductal hyperplasia similar to the human counterpart, had increased levels of NICD 
and phospho-STAT3 proteins, and increased cell proliferation as measured by using Ki-
67 immunostaining, when compared to EZH2wt/neu mice (Fig. 3-10, B). Furthermore, 
EZH2+/neu mice formed invasive mammary carcinomas significantly earlier and had 
increased levels of NICD in the tumors compared to EZH2wt/neu mice (Fig. 3-11, A-B). 
Collectively, these findings provide direct in vivo evidence that precancerous EZH2 
upregulation promotes epithelial hyperplasia with increased Notch1 expression and 
pathway activation. Our data show that EZH2 overexpression is sufficient to accelerate 
the initiation of mammary carcinomas in MMTV-neu mice.  
 
EZH2 expression is associated with NICD and CD44+/CD24- expression in human 
invasive breast cancer tissues.  
The relevance of these novel findings to human breast cancer was validated by 
examining the expression of EZH2, NICD, and CD44/CD24 proteins in tissue 
microarrays containing 107 cases of invasive breast carcinomas. Immunostained 
proteins were scored as exhibiting low or high expression according to a previously 
validated schema [39, 45]. We found a significant correlation between EZH2 and NICD 
expression, as both proteins were highly co-expressed in 55 cases (44%) and lowly co-
expressed, or not expressed at all, in 37 cases (35%) (Fisher’s exact test, 




immunostaining with CD44 and CD24. We observed that 26% of tumor tissues were 
positive for stem cells (CD44+/CD24-), EZH2 and NICD whereas 34% were negative for 
stem cells (CD44-/CD24-), EZH2 and NICD (Fisher’s exact test, p=0.0004) (Figure 3-12, 
A&C). These associations in human breast cancer underscore our in vitro and animal 
experiments and further highlight the role of EZH2 in regulating Notch1 expression and 
stem cell numbers.   
3-5. Discussion 
It was estimated that over 200,000 new breast cancer diagnoses and nearly 
40,000 breast cancer-related deaths were anticipated in the United States in 2011 alone 
[53]. Despite major advances in the diagnosis and treatment of breast cancer, there is a 
considerable gap in our understanding of the mechanisms by which breast cancer 
originates and progresses. In this study, we have identified that EZH2 has a direct 
causal role in breast cancer progression and that it is a crucial modulator of Notch1 
signaling in breast cancer. Although EZH2 has been reported to exert oncogenic 
functions in the breast, those studies were based on in vitro and xenograft models. We 
demonstrate for the first time that genetic overexpression of EZH2 accelerates breast 
cancer initiation in a transgenic mouse model of mammary tumorigenesis. 
By employing breast cancer cell lines and primary breast cancer cells derived 
from a patient tumor, we found that EZH2 expression regulates the abundance of 
cancer stem cells in vitro. Ectopic EZH2 overexpression increased the stem cell pool in 
nontumorigenic breast cells, while EZH2 downregulation reduced the breast cancer 
stem cell population in breast cancer cell lines. In accordance with our finding is an 




However, the consequences of these functions on breast cancer initiation in vivo have 
not been investigated. Our data show that genetic overexpression of EZH2 in MMTV-
neu mice decreases the latency to breast cancer initiation. The role of EZH2 in 
promoting breast stem cell expansion and breast cancer development is intriguing in 
light of our previous study showing that EZH2 protein is increased in histologically 
normal breast tissues from women up to 12 years before they develop breast cancer 
compared to controls [21, 22]. From a clinical perspective, blocking EZH2 may prevent 
breast cancer initiation in women with EZH2 overexpression in their breast epithelium. 
We show that EZH2 is a novel modulator of Notch1 expression and signaling, 
regulating Notch1-dependent expansion of breast cancer stem cells. Inhibition of 
Notch1 activity by γ-secretase inhibitors prevented EZH2-mediated induction of breast 
stem cells. By utilizing domain specific mutants of EZH2, we demonstrate that intact 
nuclear EZH2 protein is required for Notch1 gene upregulation and function on the stem 
cell pool. The association and mechanistic link between EZH2 and Notch1 was 
validated in vitro, in vivo, and in human breast cancer tissue samples.  
 Substantive data show that canonical EZH2 function is exerted through 
transcriptional repression of tumor suppressor genes through its methyltransferase 
activity on H3K27. Intriguingly, recent studies have reported that EZH2 can exert 
transcriptional activating functions in breast cancer, but the underlying mechanisms 
warrant further investigation [14-17, 54-56]. Our study defines a new role for EZH2 in 
breast cancer, by which EZH2 binds to the Notch1 promoter in a region which coincides 
with RNA Polymerase II binding and enrichment for the H3K4 activating mark, leading 




recruitment site for the transcription factor PEA3, an ETS family member who activates 
Notch1 transcription [57]. Further supporting our findings, a recent study demonstrated 
that EZH2 physically interacts with RelA and RelB proteins to promote the expression of 
NF-κB target genes in basal-like breast cancer cells, independent of the SET domain 
[16]. Another recent study demonstrated in prostate cancer cells that EZH2 binding to 
transcriptionally active gene sites occurred independent of PRC2 complex members 
and H3K27me [18]. Although independent of its canonical trimethylating mark on 
H3K27, the authors found the SET domain to be required for gene activation. These two 
studies highlight interesting discoveries within our own work. In this study, we found that 
an intact EZH2 protein, including the SET domain, was necessary for Notch1 promoter 
activity, but that the SET domain was not necessary for Notch1 promoter binding by 
EZH2. We demonstrate that the N-terminal HII domain of EZH2 is responsible and 
necessary for Notch1 promoter binding. Our data are in agreement with a previous 
study, which showed that the EZH2 N-terminal homology domains are involved in 
enhancing gene transactivation [14]. 
 In conclusion, our study advances the current understanding of the mechanisms 
of EZH2 function in breast cancer, and lends support to the emerging transcriptional 
activating role of EZH2. By providing first direct evidence that EZH2 overexpression 
accelerates breast cancer initiation in vivo, our work paves the way to targeting EZH2 to 










Figure 3-1 EZH2 levels regulate stem cell numbers in SUM149 breast cancer cells.  
(A) Immunoblots of SUM149 breast cancer cells show that downregulation of EZH2 
protein is accomplished with EZH2-targeted shRNA [shEZH2] compared to scrambled 
shRNA controls. Transient rescue of EZH2 expression in shEZH2 cells was completed 
using a myc-tagged, EZH2-encoding adenovirus [+Ad-EZH2], but rescue did not occur 
in shEZH2 cells expressing control adenovirus [+Ad-Control]. (B) EZH2 knockdown in 
SUM149 cells significantly reduces the size and numbers of mammospheres in primary 
and secondary sphere generations [7 days/generation], while re-expression of EZH2 in 
knockdown cells rescues the phenotype. Left, representative images of mammospheres 
formed after 7 days in culture [200X magnification]. Right-top, average mammosphere 
sizes ± SD in the primary generation [Student’s t-test, *p=0.04, **p=0.005]. Right-middle 
and right-bottom, average number of mammospheres ± SD per 5x104 plated cells in the 
primary and secondary generations, respectively [Student’s t-test, 1⁰ Gen. *p<0.0001, 
2⁰ Gen. *p≤0.0004]. (C) EZH2 mRNA expression is significantly higher in the parental 
SUM149 ALDH1+ flow cytometry-sorted population versus the ALDH1- sorted 
population. EZH2 mRNA expression presented as relative to β-Actin mRNA expression 
± SD [Student’s t-test, *p=0.0001]. (D) shEZH2 significantly decreased the percentage 
of SUM149 ALDH1+ cells ± SD compared to scrambled shRNA controls [Student’s t-
test, *p=0.002]. (E) shEZH2 significantly decreased the relative percentage of SUM149 
CD44+/CD24-/low cells ± SD compared to scrambled shRNA controls [Student’s t-test, 
*p=0.04].   
 
(Figure on previous page) 
 
Figure 3-2 EZH2 levels regulate stem cell numbers in MDA-MB-231 breast cancer 
cells and in patient primary breast cancer cells.  
(A) Immunoblots of MDA-MB-231 breast cancer cells show that downregulation of 
EZH2 protein is accomplished with EZH2-targeted shRNA [shEZH2] compared to 
scrambled shRNA controls. (B) shEZH2 significantly decreased the percentage of MDA-
MB-231 ALDH1+ cells ± SD compared to scrambled shRNA controls [Student’s t-test, 
*p=0.04]. (C) shEZH2 significantly decreased the relative percentage of MDA-MB-231 
CD44+/CD24-/low cells ± SD compared to scrambled shRNA controls [Student’s t-test, 
*p<0.0001] (D) Representative photomicrographs of hematoxylin and eosin [H&E] 
staining and EZH2 immunostaining of a patient tumor sample obtained from a primary 
invasive ductal breast carcinoma [Primary Tumor, 400X magnification]. The invasive 
carcinoma cells exhibited strong nuclear expression of EZH2. (E) Immunoblots of 
patient primary breast cancer cells derived from the tumor in (C) show that 
downregulation of EZH2 protein is accomplished with shEZH2 compared to scrambled 
shRNA controls. (F) In patient primary breast cancer cells, shEZH2 significantly 
decreased the percentage of CD44+/CD24-/low cells ± SD compared to scrambled 
shRNA controls [Student’s t-test, *p=0.008].   
 












Figure 3-3 EZH2 knockdown in SUM149 ALDH1+ cells decreased the growth rate 
and time to tumor initiation of in vivo breast tumors.  
(A) EZH2 knockdown significantly decreased the tumorigenicity of ALDH1+ SUM149 
cells compared to controls [mixed effects regression model, p<0.05]. Tumorigenicty 
assay using ALDH1+ and ALDH1- sorted populations of SUM149 cells expressing either 
scrambled shRNA or shEZH2. After flow cytometry sorting, 10,000 cells were injected 
into the cleared mammary fat pad of female NOD/SCID mice [n=10 mice per condition] 
and mice were monitored for tumor growth. Average tumor volume ± SEM for weeks 5-
10 post-injection for the four conditions is graphed [Student’s t-test, *p=0.004, **p=0.04]. 
(B) EZH2 knockdown significantly increased the time to tumor initiation in SUM149 
ALDH1+ cells compared to controls [Chi-squared, p<0.0001]. The table shows the 
number of mice with tumors for weeks 5-10 post-injection.   
 
(Figure on previous page) 
 
 
Figure 3-4 EZH2 downregulation reduces Notch1 and downstream signaling in 
breast cancer cells.  
(A) Heatmap of quantitative RT-PCR microarray (SABiosciences Stem Cell PCR Array) 
performed using mRNA isolated from sorted ALDH1+ SUM149 cells expressing 
scrambled shRNA or shEZH2. Upon EZH2 knockdown, Notch1 gene expression was 
one of the most significantly reduced [Student’s t-test, p<0.0001]. (B) mRNA from cells 
described in (A) were used in further quantitative RT-PCR assays analyzing expression 
of genes within the Notch signaling family. Bar graph shows that EZH2 knockdown in 
stem cells leads to deregulation of genes involved in Notch signaling. (C) Immunoblots 
of MDA-MB-231 and SUM149 breast cancer cells show that EZH2 downregulation 
reduces the expression of the intracellular, activated form of Notch1 [NICD] and 
NOTHC1 downstream targets CCND1 and CTNNB compared to controls. (D) 
Immunoblots of patient primary breast cancer cells show that EZH2 downregulation 
reduces the expression of NICD and Notch1 targets Hes1 and phosphorylated-STAT3 
[p-STAT3]. (E) Immunoblots of MDA-MB-231 and SUM149 cells show that transient 
adenoviral re-expression of EZH2 in shEZH2 cells [+Ad-EZH2] rescues NICD protein 
levels compared to adenoviral control cells [+Ad-Control].  
 




















Figure 3-5 EZH2 expression is associated with Notch1 expression in independent 
datasets of human invasive breast carcinomas.  
Significant associations [correlation coefficient > 0.6] were identified between EZH2 and 
Notch1 mRNA levels in publicly available datasets of human breast cancer tissues, first 
page, and human breast cancer cell lines, second page, utilizing Oncomine.   
 


















Figure 3-6 Notch1 is required for EZH2-induced expansion of MCF10A breast 
stem cells, part 1. 
(A) Real-time RT-PCR of MCF10A pLVX [control] and pLVX-EZH2 [conditional EZH2 
TetOn system] cells either untreated or treated with doxycycline [DOX] for 24 hours at 
1µg/ml and sorted into ALDH1- and ALDH1+ populations; mRNA expression is relative 
to GAPDH mRNA levels ± SD. Upon DOX treatment, a significant increase in EZH2 
mRNA expression is seen in both ALDH1- and ALDH1+ pLVX-EZH2 cells. Between 
these two groups specifically, EZH2 mRNA is significantly increased in the ALDH1+ 
population compared to the ALDH1- population [Student’s t-test, *p<0.0007]. (B) Real-
time RT-PCR of MCF10A pLVX-EZH2 cells either untreated or treated with DOX for 24 
hours and sorted into ALDH1- and ALDH1+ populations; mRNA expression is relative to 
GAPDH mRNA levels ± SD. Upon DOX treatment and EZH2 overexpression, Notch1 
mRNA levels significantly increase in the ALDH1+ population, but not in the ALDH1- 
population [Student’s t-test, *p=0.0001]. (C) Immunoblots of MCF10A pLVX-EZH2 cells 
show that DOX treatment results in an increase in EZH2 and NICD protein levels. Upon 
Notch1 inhibition with the γ-secretase inhibitor [GSI] for 3 days at 17nM in EZH2 
overexpressing cells, NICD protein levels are reduced. (D) Representative images of 
MCF10A pLVX and pLVX-EZH2 mammospheres formed after 7 days in culture [200X 
magnification]. (E) DOX-induced overexpression of EZH2 in MCF10A pLVX-EZH2 cells 
leads to a significant increase in mammosphere sizes and numbers compared to 
controls, which is blocked with Notch1 inhibition. For mammosphere assays, GSI 
treatment was done for each 7-day generation at 1.7nM. Top, average mammosphere 
sizes ± SD in the primary generation [Student’s t-test, *p<0.002]. Middle and Bottom, 
average number of mammospheres ± SD per 5x104 plated cells in the primary and 
secondary generations, respectively [Student’s t-test, 1⁰ & 2⁰ Gen. *p<0.0001]. 
 













Figure 3-7 Notch1 is required for EZH2-induced expansion of MCF10A breast 
stem cells, part 2. 
(A&B) DOX-induced overexpression of EZH2 in MCF10A pLVX-EZH2 cells leads to a 
significant increase in the percentage of ALDH1+ (A) and CD44+/CD24-/low (B) cells 
compared to controls, which is blocked with Notch1 inhibition. GSI was added for 3 days 
at 17nM; percentages are expressed ± SD [Student’s t-test, (A): *p=0.005, **p=0.002; 
















Figure 3-8. Full length EZH2 is required for Notch1 promoter activation and 
expansion of mammosphere sizes and numbers.  
(A) EZH2 overexpression in MCF10A pLVX-EZH2 cells leads to a significant increase in 
Notch1 promoter transcriptional activation. MCF10A pLVX and pLVX-EZH2 cells with 
and without DOX treatment were transduced with a pGreenFire lentivirus containing a 
GFP reporter gene driven by the Notch1 promoter. Transcriptional activation was 
measured as the percentage of GFP-expressing cells ± SD by flow cytometry [Student’s 
t-test, *p=0.02]. (B) Top, diagram of adenoviral, myc-tagged, EZH2 deletion mutants: 
ΔSET, ΔHI (Homology Domain I), ΔHII (Homology Domain II), and ΔNLS (Nuclear 
Localization Signal). Below, immunoblot demonstrates ectopic expression of full length 
and mutant EZH2 proteins in parental MCF10A cells and their effect on NICD protein 
levels. (C) Full length EZH2, but not any of the deletion mutants, is required for Notch1 
promoter transcriptional activation as measured by the percentage of GFP-expressing 
cells ± SD [Student’s t-test, p=0.0004]. (D) Full length EZH2, but not any of the deletion 
mutants, is required for the EZH2-induced expansion in mammosphere sizes and 
numbers. Top and Middle, average number of mammospheres ± SD per 5x104 plated 
cells in the primary and secondary generations [Student’s t-test, 1⁰ & 2⁰ Gen., 
*p<0.0001]. Bottom, average mammosphere sizes ± SD in the primary generation 
[Student’s t-test, *p=0.005]. 
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Figure 3-9 EZH2 binds to the Notch1 gene promoter in benign breast cells, breast 
cancer cell lines and in patient primary breast cancer cells. 
(A) Diagram of the Notch1 promoter regions analyzed for EZH2 binding in chromatin 
immunoprecipitation [ChIP] assays. EZH2 was found to bind region “B” at -1.2kb; only 
ChIP real-time PCR data using primers designed for site “B” are shown. (B) ChIP 
assays were performed using nontumorigenic primary breast cells expressing control, 
full length EZH2, EZH2ΔSET or EZH2ΔHII. Primers flanking the GAPDH promoter were 
used as negative binding controls, and primers flanking the MYT1 promoter, a known 
H3K27me3-repression target of EZH2, were used as positive binding controls. EZH2 
binds the Notch1 promoter independent of H3K27me3 and SUZ12, but coincides with 
RNA Polymerase II binding and enrichment for the transcriptional activating mark 
H3K4me2. The N-terminal HII domain is required for EZH2 binding whereas the C-
terminal SET domain is dispensable. (C) ChIP assays as described in (B) were 
perfomed using MDA-MB-231 breast cancer cells expressing scrambled control shRNA 
or shEZH2. Endogenous EZH2 binds the Notch1 promoter with similar associations as 
observed in (B), and binding is blocked with shEZH2. (D) ChIP assays as described in 
(B) were performed using patient primary breast cancer cells. Endogenous EZH2 binds 
to the Notch1 promoter with similar associations as observed in (B). [Student’s t-test, *p 
<0.05} 
 














Figure 3-10 Characterization of EZH2+/neu and EZH2wt/neu transgenic mice. 
(A) Left, representative images of whole mounts of mammary glands from 16 weeks old 
virgin female mice show that EZH2+/neu glands exhibit ductal hyperbranching 
compared to EZH2wt/neu glands controls. [100X magnification]. Right, graph shows the 
average number of tertiary branches ± SD in whole mounts preparations described in 
(A) [Student’s t-test, *p<0.05]. (B) Representative histological sections at 8 and 16 
weeks of age [400X magnification]; EZH2+/neu mammary glands show upregulation of 
EZH2 protein in the nuclei of breast epithelial cells. At 8 weeks, EZH2+/neu mice exhibit 
ductal hyperplasia, and at 16 weeks atypical intraductal hyperplasia becomes evident 
(arrow); changes were not seen in controls for the indicated timepoints. EZH2+/neu 
mammary glands also show increased expression of NICD, phosphorylated-STAT3 and 
Ki67 compared to EZH2wt/neu mammary glands.  
 








Figure 3-11 Transgenic EZH2 overexpression accelerates tumor initiation and 
upregulates Notch1 in MMTV-neu mice. 
(A) Kaplan Meier curve shows that EZH2+/neu mice formed mammary carcinomas 
significantly earlier than EZH2wt/neu mice [Log-rank test, p<0.0001]. (B) Representative 
photomicrographs of breast carcinomas from EZH2+/neu and control EZH2wt/neu mice 







Figure 3-12 EZH2 expression is associated with NICD and CD44+/CD24- 
expression in human invasive breast cancer tissues.  
(A) Representative images of three primary human invasive breast carcinomas (n=107 
patients) stained for H&E and immunostained for EZH2, NICD and CD44/CD24 [400X 
magnification] (B) The table shows the distribution of EZH2 and NICD protein 
expression in 107 primary invasive breast carcinomas scored from immunostained 
tissue microarrays; 43.9% of tumors exhibited high expression of both EZH2 and NICD 
[Fisher’s Exact Test, p<0.0001, 2-tailed]. (C) The table shows the distribution of EZH2, 
NICD and CD44/CD24 protein expression in 70 primary invasive breast carcinomas; 
25.7% of tumors exhibited high expression of EZH2, NICD and CD44+/CD24- [Fisher’s 
Exact Test, p=0.0004, 2-tailed]. 
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4-1. Discussion and Future Directions 
Breast cancer development and metastasis are complex processes, but through 
research, our understanding of these processes has evolved. The aim of this thesis has 
been to delve into the mechanisms underlying the importance of EZH2 overexpression 
in breast malignancies. Before our studies, EZH2 was highly associated with aggressive 
breast cancer and metastasis, but the work presented here has directly demonstrated 
that downregulation of EZH2 in breast cancer cells leads to a decrease in metastatic 
burden. In all, our findings have revealed important and novel functional links between 
EZH2, stem cells and breast cancer migration and invasion, and the underlying 
mechanisms involving EZH2-mediated regulation of p38 and Notch1 signaling 
pathways. This work establishes EZH2 as regulator of breast cancer progression and 
metastasis. However, as in all research, answers to certain questions inevitably lead to 
the development of new questions and research goals. Here, many of the new 
questions generated by the reported data will be addressed with proposed future 
directions.  
The observed interaction between EZH2 and p38 proteins through 
immunoprecipitation (IP) experiments in Chapter 2 has raised several interesting and 
important questions. First, does EZH2 have preferential binding affinity for the 




Another related question might be where does this interaction occur, in the cytoplasm or 
the nucleus, or both? Although IPs were conducted using pan p38 and phosphorylated-
p38 (p-p38) antibodies, the question of preferential affinity could not be answered in 
these experiments. The pan p38 antibodies that were used recognize both p38 and p-
p38 species, so even though probing with a p-p38 antibody in a Western blot shows 
binding, an interaction between unphosphorylated p38 cannot be excluded.  
As EZH2 predominantly localizes to the nucleus, it may seem more likely that 
EZH2 preferentially binds p-p38 since it is usually accumulates in the nucleus after 
activation [1, 2]. However, unphosphorylated p38 can be found in the cytoplasm and the 
nucleus, and it has been reported that phosphorylated p38 can be trafficked out of the 
nucleus into the cytoplasm by its substrate MK2 [3, 4]. Additionally, in a study where an 
activating function for EZH2 in actin polymerization was defined, it was also revealed 
that EZH2 can exist in the cytoplasm [5]. This cytosolic EZH2 retained 
methyltransferase capabilities as it was found to complex with the other core PRC2 
members SUZ12 and EED in the cytoplasm, so our data demonstrating that SUZ12 and 
EED immunoprecipitate with p38 does not aid in answering the question of where these 
interactions occur. A cytosolic role for EZH2 has been implicated in research conducted 
in our laboratory as well. For instance, immunohistochemistry for EZH2 in mouse and 
human breast tumors does show a primary localization of EZH2 to the nuclei of cancer 
cells, but a lighter staining in the cytoplasm can also be seen (Figures 1-9, 1-10, 2-12). 
Also, in Western blot analyses, EZH2 has been seen in our laboratory to be present in 
both cytoplasmic and nuclear fractionations, although much lower in cytoplasmic 




nuclear fractionations may answer the important localization question, the question of 
possible preferential affinity cannot be resolved in this manner.  
In order to determine if EZH2 has a preference for unphosphorylated or p-p38, a 
couple of different experiments could be conducted. First, immunoprecipitates collected 
using an EZH2 antibody could be run out via 2-dimensional gel electrophoresis, which 
allows for the separation of proteins by size and isoelectric point. As phosphorylated 
proteins are more acidic than their unphosphorylated counterparts, this assay should 
make them distinguishable if present. Second, lysates could be treated in vitro with 
Lambda Phosphatase before conducting IPs. If the phosphorylation mark is required for 
EZH2 binding, the loss of phosphorylation on p38 caused by phosphatase treatment 
should inhibit binding when compared to untreated controls.     
Another significant question that the interaction between EZH2 and p38 
generates is if there is a functional relevance to the binding. For example, does the 
binding promote the activation of p38 or ensure the stability of p-p38, or does it just 
coincide with the correlation between EZH2 and p-p38 protein levels in breast cancer 
cells with no functional relevance? In muscle stem cells, it has been recently 
demonstrated that EZH2 binds to p38α in nuclear extracts in association with the p38 
upstream activator MKK6 [6]. EZH2 and p38α were detected on the promoter region of 
Pax7, a typical marker of stem cells, only after MKK6-mediated activation of p38. This 
study supports our findings of an interaction between EZH2 and p38, and suggests that 
the binding these two proteins may be functional as it was necessary for repression of 
Pax7 in another system. In breast cancer cells, it would be of interest to see if MKK3 or 




complex with EZH2 and p38 through IPs [3]. These experiments could be expanded 
with the use of adenoviral constructs that express constitutively active forms of MKK3 or 
MKK6. Would the expression of these constructs, which would lead to p38 activation, 
lead to enhanced binding of p38 with EZH2? Additionally, does p38 co-occupy with 
EZH2 at PRC2 target genes and, if so, is its activation necessary for this recruitment?  
It would also be of interest to determine what domains of EZH2 are necessary for 
binding with p38. Expression of the EZH2 mutants described in Chapter 3 in association 
with IP experiments could help to answer this question. Functionally, if a certain domain 
is deemed required for binding, the expression of its corresponding mutant could be 
used to determine if the activity of p-p38 is dependent on binding, as measured by the 
phosphorylation of downstream targets. It must also be kept in mind, however, that the 
binding between EZH2 and p38 may not be direct as another cofactor may be 
necessary for the interaction. The identification of other binding partners could be 
accomplished with IPs followed by mass spectrometry.  
On a more basic level, experiments could be performed to see if EZH2 binding to 
p-p38 leads to stabilization. The use of proteasomal inhibitors, such as epoxomicin and 
lactacystin, could be used in scrambled control and shEZH2 breast cancer cells. If high 
EZH2 levels lead to increased p-p38 protein stability, the use of such inhibitors in the 
EZH2 knockdown cells should allow for a greater accumulation of p-p38 than what 
would be observed in treated control cells. Additionally, it must be considered that the 
increase in p-p38 levels seen with high EZH2 expression may be the result of PRC2-




mRNA and protein levels of known MAPK-targeted phosphatases in control and EZH2 
knockdown cells would easily address this issue.  
The last set of questions generated from the interaction between EZH2 and p38 
relate to the normal catalytic functions of these proteins. For instance, does the 
association lead to the methylation of p38 by EZH2? The post-translational methylation 
of several non-histone proteins has been reported in recent years, and in many cases, 
the methylation leads to enhanced stability or activity of these proteins [7]. We have 
demonstrated in preliminary experiments that PRC2 can methylate p38α in vitro.  As 
knockdown of EZH2 was found to decrease levels of all p-p38 isoforms, in vitro 
experiments should be extended to include the other three isoforms. Moreover, in vivo 
experiments should be performed to see if the methylation occurs in live cells using 
metabolic labeling and antibodies that recognize methylated residues. Analysis of the 
p38 amino acid sequence using PMeS (Prediction of protein Methylation Sites), did not 
suggest any lysine residues as potential sites for methylation, but two arginine residues 
located at 189 and 237 were proposed with a threshold value above 0.5. If in vivo 
experiments show promising results, mass spectrometry of methylated p38 proteins 
should be performed in order to identify potential methylation sites. Most importantly, 
though, if methylation is confirmed in vivo, it should be determined if the methylation 
regulates the activation and activity of p-p38.  
Alternately, does the interaction between EZH2 and p38 lead to the 
phosphorylation of EZH2 by p-p38? It has been published in recent years that EZH2 
can be phosphorylated by several kinases affecting its activity. Most importantly, 




phosphorylating EZH2 on threonine 372, which enhances its repression of Pax7 [6]. 
Additionally, phosphorylation of EZH2 by AKT on serine 21 decreases H3K27me3 
levels, leads to derepression of silenced genes and contributes to tumor progression [8]. 
Several other studies have demonstrated that cyclin dependent kinases phosphorylate 
EZH2 at threonines 350 and 492 [9-12]. Phosphorylation of these two residues appears 
to have contrasting roles in EZH2 activity as phosphorylation of threonine 350 and of 
threonine 492 positively and negatively impact PRC2 functions, respectively. These 
studies in EZH2 phosphorylation emphasize the need for further interrogation of the 
interaction between EZH2 and p38. Numerous serine and threonine phosphorylation 
sites are predicted on EZH2, some specifically for MAPKs, utilizing several 
phosphorylation prediction software programs implicating a need for further research. If 
a phosphorylation event does occur by p38 on EZH2, it would be intriguing to see if an 
effect on EZH2 activity is rendered. We have demonstrated that inhibition of p-p38 
activity does not affect EZH2 or H3K27me3 protein levels, so perhaps phosphorylation 
of EZH2 may influence the recruitment of EZH2 and PRC2 to target genes.  
 Our findings in Chapter 3 related to the EZH2-mediated regulation of stem cell 
numbers and Notch1 signaling raise several questions as well. First, a fusion of the 
ideas presented in Chapter 2 with those in Chapter 3 can be imagined. Two 
independent studies have found that induction of EMT in human mammary epithelial 
cells generates cells with stem-like properties [13, 14]. We have shown separately that 
high EZH2 expression in breast cancer cells promotes EMT and an expansion in CSCs. 
Experiments should be extended to determine the levels of epithelial or mesenchymal 




stem populations based on expression of ALDH1+ and CD44+/CD24-/low. Additionally, 
control and shEZH2 breast cancer cells grown using the mammosphere assay should 
be assayed for the expression of EMT proteins and compared to cells grown under 
normal tissue culture conditions. Based on the recent studies, it is hypothesized that 
down-regulation of EZH2 in CSCs will lead to an epithelial-like protein expression 
pattern compared to controls.  
 Through the use of established cell surface marker proteins and the 
mammosphere assay, we were able to interrogate the effects of EZH2 up- and 
downregulation on CSC numbers. It has been demonstrated by other research groups 
using the breast cancer cell lines MDA-MB-231 and SUM149 that cells isolated through 
the expression of these cell surface markers and through mammosphere assays are 
indeed bona fide CSCs with the required properties discussed in Chapter 1 [15-17]. 
Although previously shown, it would be beneficial if we were to personally demonstrate 
tumor initiating capacity in our isolated CSC populations. To do so, limiting dilution 
xenograft transplantations should be conducted in immunocompromised mice with 
isolated “potential” CSCs. As we have shown that knockdown of EZH2 decreases the 
number of CSCs in vitro, we would expect that shEZH2 CSCs would have less tumor 
initiating capacity over several transplantations. Moreover, cells deemed non-CSCs 
after sorting, should show low to no tumor initiating capacity over several 
transplantations.  
 Our findings that EZH2+/neu transgenic mice have increased Notch1 expression 
and earlier tumor initiation create further research questions. For instance, even though 




explicitly say that this is due to an effect of EZH2 regulating stem cells in the murine 
mammary gland. In order to show a direct correlation between EZH2 and stem 
cells/CSCs in these mouse models, primary cells should be collected from early non-
tumorigenic and late malignant mammary glands. Establishing the percentage of stem-
like cells obtained from these glands could be accomplished using the aforementioned 
cell surface marker proteins and the mammosphere assay. Additionally, 
immunohistochemistry for CD44/CD24 in both early and late mammary glands would 
provide valuable information. As we observed a concomitant increase in stem cell 
numbers with EZH2 overexpression in vitro, it is expected that EZH2+/neu mice will 
contain more stem cells and CSCs in nonmalignant and tumorigenic breast tissues, 
respectively, when compared to EZH2wt/neu mice. Furthermore, it can be asked if 
treatment of these mice with a γ-secretase inhibitor (GSI) will have an effect on tumor 
initiation. We found that EZH2+/neu mice formed breast tumors significantly earlier than 
EZH2wt/neu mice, so it can be hypothesized that treatment of these mice with GSI will 
lead to later development of breast tumors. It would also be interesting to determine the 
number of CSCs in the mammary glands after these mice develop tumors and are 
treated with GSI. Will GSI reduce the number of CSCs present in the tumors?  
Additionally, the same GSI treatment could be used in xenograft models. We found that 
control SUM149 ALDH1+ cells had earlier tumor initiation and a faster tumor growth rate 
compared to shEZH2 ALDH1+ and all ALDH1- cells. Would GSI treatment of mice 
injected with SUM149 ALDH1+ cells prevent this earlier tumor initiation and increased 




 Lastly, the data demonstrating that EZH2 localizes to the Notch1 promoter in a 
manner independent of H3K27me3 and PRC2 and instead correlates with 
transcriptional activation marks raises the question of cofactors. Are other proteins 
localizing with EZH2 to this gene promoter, and, if so, is their presence required for 
EZH2 recruitment and subsequent gene activation? IPs using antibodies targeted 
against EZH2 followed by mass spectrometry may allow for identification of potential 
cofactors. Additionally, conducting IPs in sorted stem and non-stem cell populations 
would be of particular interest. Would it be found that EZH2 binds the Notch1 promoter 
in both populations or only preferentially in stem cell-like populations?  
4-2. Clinical and Therapeutic Implications 
It has been established that EZH2 plays a crucial role in stem cell maintenance 
and in many types of tumor development. However, there are no therapies currently 
available that target histone methylation or EZH2. In the laboratory setting, DZNeP has 
emerged as the most promising PRC2 inhibitor and it has been widely used to decrease 
EZH2 protein expression. But, the effect of DZNeP on histone methylation is considered 
to be global versus EZH2-specific, so there is warranted concern in its potential 
therapeutic use as it may affect many processes requiring histone methylation  [18-20]. 
Nevertheless, DZNeP has been found to have anti-tumor activity in numerous cancer 
cells, including breast, making it a valuable research tool [21]. A recent study from 
researchers at GlaxoSmithKline has introduced the small-molecule inhibitor GSK126, 
which they have characterized as a potent and highly selective inhibitor of EZH2 
methyltransferase activity [22]. They demonstrated in lymphoma cells that GSK126 was 




these tumors expressed the Y641 EZH2 mutant, which has enhanced H3K27me3 due 
to altered substrate preferences. Hopefully, more work utilizing this inhibitor in cancers 
that overexpress wild type EZH2 will emerge, implicating a wider potential application 
for this drug. In regards to therapeutically targeting EZH2 in human cancers, however, 
caution should be taken in certain malignancies. Mutations of EZH2 in myeloid cancers 
have been shown to lead to inactivation and loss of gene repression, thus it is vital to 
determine the activation status of EZH2 in a tumor before initiating treatment strategies 
aimed at inhibiting EZH2 [23].  
As interactions between PcG gene regulation and other forms of epigenetic 
modifications have emerged, it may be promising to use therapies targeted against 
DNMTs and HDACs. Many inhibitors for these proteins are available with clinical trials 
currently underway [18, 24]. Interestingly, it has been revealed that simultaneous 
treatment with DNMT and HDAC inhibitors in cell and animal models has anti-
tumorigenic effects [25]. Moreover, combinatorial treatment of human leukemia cells in 
vitro with DZNeP and an HDAC inhibitor led to a synergistic apoptotic effect  [26].These 
studies emphasize the complex nature of the interactions between different epigenetic 
marks.  
The link between EZH2 and CSCs implies that therapies targeting pathways 
involved in CSCs may be beneficial in patients with tumors expressing high EZH2 
protein levels. Indeed, it has been postulated that CSCs within a tumor are resistant to 
chemotherapy and radiation, and are likely to cause relapse in patients [27, 28]. This 
may due to the fact that conventional therapeutics efficiently target actively proliferating 




the CSC population [29, 30]. It has been demonstrated in a mouse xenografts that 
treatment with oncolytic adenoviruses was effective in killing the CD44+/CD24-/low 
population and preventing tumor formation [31]. Another study has shown that treatment 
of mouse xenografts with the CSC active compound 8-quinolinol in combination with the 
mitotic inhibitor paclitaxel shows anti-tumor activity and prevents relapse [32]. But, as 
we have found the expression of Notch1 in CSCs to be regulated by EZH2, therapies 
targeted against Notch signaling in patients with high EZH2 expression may be 
promising in eliminating resilient CSCs. Studies using monoclonal antibodies targeted 
against Notch receptors and ligands have revealed a decrease in tumorigenic activities 
and in the frequency of CSCs [33, 34]. Likewise, the use of GSI in mouse xenograft 
leukemia models and in transgenic ERBB2-breast cancer models demonstrates 
promising anti-tumor effects [35, 36]. Specifically, in another study researchers 
discovered that treatment of mice injected with breast cancer cells with the Notch1 GSI 
DAPT led to a significant decrease in brain metastases [37]. Although all of the research 
into inhibiting CSCs in vivo is vital to a progression in breast cancer treatment, it is yet 
to be seen how such methods will affect human breast tumors. Additionally, the effect of 
these inhibitory methods on the normal stem cell populations within the mammary 
epithelium must be taken into account along with possible side effects. Taken together, 
these studies show encouraging results for a number of methods in targeting CSCs that 
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